

Technical guide for the **ELABORATION OF MONOGRAPHS**



European Pharmacopoeia

EDQM
8th Edition
2022

English version

2022

Making copies of this file for commercial purposes or posting it on a website for which access is charged is strictly prohibited. Re-use of the file, in whole or in part, requires that the source be clearly cited and the EDQM (publications.info@edqm.eu) be informed.

European Directorate for the Quality of Medicines & HealthCare (EDQM)
Council of Europe
7, allée Kastner
CS 30026
F-67081 STRASBOURG
FRANCE

Cover image: © EDQM – Council of Europe
Editorial director: **Dr P. Doerr**

Page layout: **EDQM**

www.edqm.eu

© Council of Europe, 2022

Technical guide for the
ELABORATION OF MONOGRAPHS

European Pharmacopoeia

8th Edition
2022

TECHNICAL GUIDE FOR THE ELABORATION OF MONOGRAPHS

8th Edition – 2022

TABLE OF CONTENTS

I.	INTRODUCTION	1
I.1	PURPOSE OF THE GUIDE	1
I.2	ANALYTICAL PROCEDURES	1
I.3	EQUIPMENT	2
I.4	QUANTITIES	2
I.5	REAGENTS	4
I.6	COMMERCIAL NAMES	4
I.7	REFERENCE STANDARDS.....	4
II.	MONOGRAPHS ON SUBSTANCES FOR PHARMACEUTICAL USE	5
II.1	TITLE.....	6
II.2	FORMULAE, MASSES AND CAS NUMBERS.....	6
II.3	DEFINITION	7
II.3.1.	<i>Combinations</i>	7
II.3.2.	<i>Content</i>	7
II.4	PRODUCTION	8
II.5	CHARACTERS	8
II.5.1.	<i>Appearance</i>	9
II.5.2.	<i>Taste</i>	9
II.5.3.	<i>Odour</i>	9
II.5.4.	<i>Solubility</i>	9
II.5.5.	<i>Stability factors</i>	9
II.5.6.	<i>Hygroscopicity</i>	9
II.5.7.	<i>Solid-state properties</i>	10
II.5.8.	<i>Other characteristics</i>	10
II.5.9.	<i>Behaviour in solution</i>	10
II.6	IDENTIFICATION	11
II.6.1.	<i>General</i>	11
II.6.2.	<i>First and second identification series</i>	12
II.6.3.	<i>Infrared absorption spectrophotometry</i>	13
II.6.4.	<i>Absorption spectrophotometry (ultraviolet and visible)</i>	14
II.6.5.	<i>Melting point, freezing point and boiling point</i>	15
II.6.6.	<i>Identification of substances that have one or more stereocentre(s)</i>	15
II.6.7.	<i>Thin-layer chromatography</i>	16
II.6.8.	<i>Gas chromatography and liquid chromatography</i>	16
II.6.9.	<i>Chemical reactions</i>	16
II.7	TESTS	17
II.7.1.	<i>General</i>	17
II.7.2.	<i>Title of tests</i>	18
II.7.3.	<i>Solution S</i>	18
II.7.4.	<i>Appearance of solution</i>	19
II.7.4.1.	<i>Clarity and degree of opalescence (2.2.1)</i>	19
II.7.4.2.	<i>Degree of coloration of liquids (2.2.2)</i>	20

II.7.5.	<i>pH and Acidity or alkalinity</i>	20
II.7.6.	<i>Optical rotation (2.2.7)</i>	22
II.7.7.	<i>Absorption spectrophotometry (ultraviolet and visible) (2.2.25)</i>	23
II.7.8.	<i>Related substances</i>	23
II.7.8.1.	Thin-layer chromatography (2.2.27) and high-performance thin-layer chromatography for herbal drugs and herbal drug preparations (2.8.25).....	28
II.7.8.2.	Liquid chromatography (2.2.29).....	28
II.7.8.3.	Gas chromatography (2.2.28).....	34
II.7.8.4.	Capillary electrophoresis (CE) (2.2.47).....	34
II.7.9.	<i>Readily carbonisable substances</i>	35
II.7.10.	<i>Foreign anions and/or cations</i>	35
II.7.11.	<i>Elemental Impurities</i>	36
II.7.12.	<i>Loss on drying (2.2.32)</i>	36
II.7.13.	<i>Thermogravimetry (2.2.34)</i>	37
II.7.14.	<i>Semi-micro determination of water (2.5.12) – volumetric Karl-Fischer</i>	37
II.7.15.	<i>Micro determination of water (2.5.32) – coulometric Karl-Fischer</i>	38
II.7.16.	<i>Gas chromatographic determination of water</i>	38
II.7.17.	<i>Determination of water by distillation (2.2.13)</i>	38
II.7.18.	<i>Sulfated ash (2.4.14)</i>	38
II.7.19.	<i>Residue on evaporation</i>	39
II.7.20.	<i>Residual solvents (2.4.24)</i>	39
II.7.21.	<i>Bacterial endotoxins</i>	39
II.8	ASSAY.....	40
II.8.1.	<i>Absorption spectrophotometry (ultraviolet and visible) (2.2.25)</i>	41
II.8.1.1.	Direct measurement.....	41
II.8.1.2.	Measurement after a colour reaction.....	41
II.8.2.	<i>Volumetric analysis</i>	41
II.8.3.	<i>Chromatography-based techniques</i>	42
II.8.4.	<i>Determination of nitrogen by sulfuric acid digestion (2.5.9)</i>	42
II.9	STORAGE.....	42
II.10	LABELLING.....	43
II.11	IMPURITIES.....	43
II.12	FUNCTIONALITY-RELATED CHARACTERISTICS.....	44
III.	ANALYTICAL VALIDATION	45
III.1	DEFINITIONS AND TERMINOLOGY.....	45
III.1.1.	<i>Introduction</i>	45
III.1.2.	<i>Types of analytical procedures to be validated</i>	45
III.1.3.	<i>Validation characteristics and requirements</i>	46
III.1.4.	<i>Glossary</i>	47
III.2	METHODOLOGY.....	48
III.2.1.	<i>Introduction</i>	49
III.2.2.	<i>Specificity</i>	49
III.2.2.1.	Identification.....	49
III.2.2.2.	Assays and impurity tests.....	50
III.2.3.	<i>Linearity</i>	50
III.2.4.	<i>Range</i>	51
III.2.5.	<i>Accuracy</i>	52
III.2.5.1.	Assay.....	52
III.2.5.2.	Impurities (quantitation).....	52
III.2.5.3.	Recommended data.....	52
III.2.6.	<i>Precision</i>	53
III.2.6.1.	Repeatability.....	53
III.2.6.2.	Intermediate precision.....	53
III.2.6.3.	Reproducibility.....	53
III.2.6.4.	Recommended data.....	53
III.2.7.	<i>Detection limit</i>	53
III.2.7.1.	Based on visual evaluation.....	53
III.2.7.2.	Based on signal-to-noise ratio.....	53
III.2.7.3.	Based on the standard deviation of the response and the slope.....	54
III.2.7.4.	Recommended data.....	54
III.2.8.	<i>Quantitation limit</i>	54

III.2.8.1. Based on visual evaluation	54
III.2.8.2. Based on signal-to-noise ratio	54
III.2.8.3. Based on the standard deviation of the response and the slope	55
III.2.8.4. Recommended data	55
III.2.9. <i>Robustness</i>	55
III.2.10. <i>System suitability testing</i>	56
III.3 SPECIFIC APPLICATION TO ANALYTICAL PROCEDURES USED IN THE PH. EUR.....	56
III.3.1. <i>Optical rotation (2.2.7)</i>	56
III.3.1.1. Introduction	56
III.3.1.2. Identification	56
III.3.1.3. Tests	57
III.3.2. <i>Absorption spectrophotometry (ultraviolet and visible) (2.2.25)</i>	57
III.3.2.1. Identification	57
III.3.2.2. Limit test	57
III.3.2.3. Assay.....	58
III.3.3. <i>Non-instrumental limit tests</i>	58
III.3.3.1. Appearance of solution (2.2.1 and 2.2.2)	58
III.3.3.2. Acidity or alkalinity	58
III.3.3.3. Limit tests for anions/cations (2.4).....	58
III.3.4. <i>Atomic absorption spectrometry (2.2.23)</i>	59
III.3.4.1. Specificity	59
III.3.4.2. Calibration.....	59
III.3.4.3. Matrix effects	60
III.3.4.4. Detection and quantitation limit (based on the standard deviation of the blank).....	60
III.3.5. <i>Separation techniques</i>	60
III.3.5.1. Thin-layer chromatography (2.2.27)	61
III.3.5.2. Liquid chromatography (2.2.29).....	61
III.3.5.3. Gas chromatography (2.2.28).....	63
III.3.6. <i>Semi-micro determination of water (2.5.12)</i>	64
III.3.7. <i>Volumetric titrations (2.5.11, 2.2.19, 2.2.20)</i>	65
III.3.8. <i>Peptide identification by nuclear magnetic resonance spectrometry (2.2.64)</i>	67

1

2 I. INTRODUCTION

3 I.1 PURPOSE OF THE GUIDE

4 This document is a guide for the authors of monographs and also a means of communicating the
5 principles for the elaboration and revision of monographs to the users of the European
6 Pharmacopoeia (Ph. Eur.), especially industry, licensing authorities and official medicines control
7 laboratories. Since the principles applied and guidance given for the elaboration and revision of
8 monographs should be the same as those applied by licensing authorities, this Technical guide may
9 also serve as a guideline in the elaboration of specifications intended for inclusion in marketing
10 authorisation applications.

11 It is necessary to bear in mind that a monograph will be a mandatory standard and must be
12 applicable in marketing authorisation procedures in all states parties to the Convention on the
13 Elaboration of a European Pharmacopoeia (hereinafter the “European Pharmacopoeia
14 Convention”).

15 The term “elaboration” used hereinafter in this guide covers both “elaboration” and/or “revision”.

16 I.2 ANALYTICAL PROCEDURES

17 The analytical procedures chosen for the identification tests, purity tests and assay(s) constituting
18 the bulk of a pharmacopoeial monograph are preferably those already described and utilised in the
19 Ph. Eur. In this context, the author of a monograph is referred not only to the General Chapters
20 of the Ph. Eur. but also to published monographs on similar materials. The above considerations
21 are intended to ensure a reasonable degree of harmonisation within the Ph. Eur. and only apply in
22 cases where the procedures are found to be adequate for the specific purposes. However, due
23 attention is also to be paid to the development of new procedures that offer significant
24 improvements in terms of sensitivity, precision, accuracy or specificity/selectivity.

25 Analytical procedures included in monographs are validated as described in part III
26 (ANALYTICAL VALIDATION) and other relevant specific parts of this guide. Validation reports
27 are provided to the EDQM but are not published or otherwise provided to users.

28 The analytical procedures included in a monograph are validated and further verified in two or more
29 laboratories. One of these may be the supplier of the procedure who initially validated it.

30 The laboratory reports on the validation and verification are to be provided to the EDQM to ensure
31 future traceability.

32 The instructions for any analytical procedure cover all factors that may influence the results and
33 that are deemed essential for an experienced analyst working according to acknowledged laboratory
34 practices to be able to perform the analysis without necessarily having any prior knowledge of the
35 investigation in question. Variations in the description of similar analytical procedures are to be
36 avoided.

37 If it is expected that an analytical procedure will be used generally or if it requires a lengthy
38 description and is used more than once, it may be proposed for inclusion in the general
39 chapters of the Ph. Eur., to be referred to in the individual monographs. The procedures are
40 prescribed on the scale conventionally applied in the Ph. Eur. except in cases where for reasons
41 of availability of the material to be analysed, or because of its toxicity or its cost, work on a small
42 scale would be advantageous.

43 I.3 EQUIPMENT

44 If the equipment utilised for an analytical procedure is not generally available in the states parties
45 to the European Pharmacopoeia Convention, it must be possible to have it constructed according to
46 its description in the Ph. Eur.

47 I.4 QUANTITIES

48 In prescribing the quantities (i.e. masses and volumes of substances, reagents and solvents to be
49 taken for analysis), it is the practice of the Ph. Eur. to indicate, with the given number of significant
50 figures, the exact target quantity value that is to be measured (see paragraph on Quantities in the
51 *General Notices*). It is therefore necessary to take this aspect into consideration when drafting
52 pharmacopoeial texts.

53 Table 1, which provides estimations of relative uncertainty, is to be consulted as a guide for
54 minimising errors in the preparation of analytical solutions.

55 In order to avoid either the use of extremely low amounts or unnecessarily large quantities of
56 solvents, a dilution series will often have to be prescribed for the preparation of dilute solutions
57 used particularly for spectrophotometric measurement. In this case, not all combinations of
58 (usually two or three) dilution steps will contribute equally to the random error of the dilution
59 procedure. If critical for the purpose, the optimal dilution is prescribed in consideration of the
60 relative errors (capacity tolerance divided by nominal volume) associated with the various sizes of
61 volumetric pipettes and volumetric flasks commonly used for these operations. The standard
62 formula for estimating relative dilution error is the square root of the sum of the squares of
63 individual relative errors.

64 Tables giving the optimal number and nature of dilution steps needed to achieve a given dilution
65 ratio, based upon given specifications for the capacity tolerances of volumetric glassware, are
66 available in the literature. For guidance, see Table 2 (note that these factors do not include reading
67 errors).

68

69 *Table 1 – Relative uncertainties in the preparation of analytical solutions*

Concentration to be prepared	Preparation of solution	Percentage relative uncertainty		
		Mass	Volume	Total
10 g/1000 mL	10 g/1000 mL	< 0.01	0.05	0.05
	1 g/100 mL	0.02	0.12	0.12
	0.5 g/50 mL	0.04	0.17	0.17
	0.25 g/25 mL	0.08	0.23	0.24
	0.1 g/10 mL	0.02	0.50	0.54
1 g/1000 mL	1 g/1000 mL	0.02	0.05	0.05
	0.5 g/500 mL	0.04	0.07	0.08
	0.25 g/25 mL	0.08	0.23	0.24
	100 mg/100 mL	0.2	0.12	0.23
	50 mg/50 mL	0.4	0.17	0.43
	10 mg/10 mL	2.0	0.50	2.06
0.1 g/1000 mL	100 mg/1000 mL	0.2	0.05	0.21
	50 mg/500 mL	0.4	0.07	0.41
	25 mg/250 mL	0.8	0.08	0.80
	10 mg/100 mL	2.0	0.12	2.0
	5 mg/50 mL	4.0	0.17	4.0
	1 mg/10 mL	20.0	0.50	20.0
0.01 g/1000 mL	10 mg/1000 mL	2.0	0.05	2.0
	5 mg/500 mL	4.0	0.07	4.0
	1 mg/100 mL	20.0	0.12	20.0

70 An uncertainty of 0.2 mg for the weighing procedure has been assumed for the calculations of the percentage relative uncertainties.
71

72

73

74 *Table 2 – Relative errors for dilution with analytical glassware (pipettes P/flasks F)*

Concentration ratio	No. of steps	Step 1		Step 2		Relative error
		P	F	P	F	
1/2	1	25	50			0.16
1/2.5	1	20	50			0.18
1/5	1	20	100			0.17
1/10	1	25	250			0.13
1/12.5	1	20	250			0.16
1/30	1	15	500			0.20
1/50	1	20	1000			0.15
1/100	1	25	250	25	250	0.18
1/125	2	20	250	25	250	0.20
1/160	2	25	1000	25	100	0.19
1/200	2	25	500	25	100	0.18
1/250	2	20	250	25	500	0.20
1/400	2	25	250	25	1000	0.18
1/500	2	20	500	25	500	0.20
1/1000	2	20	1000	25	500	0.20

75 Adapted from R.B. Lam and T.L. Isenhour, Minimizing relative error in preparation of standard solutions by judicious choice of volumetric
76 glassware, *Analytical Chemistry*, 1980, **53**, 1158-1161.
77

78 I.5 REAGENTS

79 When the quality of a reagent in one or more respects is critical for its intended use, it must be
80 carefully defined by prescribing appropriate tests to demonstrate its suitability. Typically,
81 analytical grade reagents are employed, in which case it is sufficient to give the name of the
82 reagent, the CAS number and its formula.

83 Whenever possible, the reagent substances, reagent solutions, buffer solutions, volumetric solutions
84 and standard solutions already described in Ph. Eur. general chapter 4. *Reagents* are to be
85 employed. Simple solutions of reagents that are prepared for single use are to be described in the
86 monograph itself.

87 The use of reagents that are acknowledged to be extremely toxic or otherwise hazardous (e.g.
88 carcinogenic) is to be avoided, especially in circumstances where their dangerous properties are
89 difficult to control (e.g. when handled as fine powders or in spray reagents). The use of those
90 substances that are prohibited or restricted in one or more of the states parties to the European
91 Pharmacopoeia Convention is also to be avoided (mercury containing reagents, substances
92 regulated through [REACH regulation annex XIV](#), etc.). In monographs where these reagents are
93 still described, the group of experts (GoE) concerned should initiate a revision of the relevant test
94 with the objective of avoiding such reagents where possible.

95 I.6 COMMERCIAL NAMES

96 Commercial names for chromatography columns/plates and solvents/titrants/conditions for water
97 determinations are always given as footnotes in draft monographs. Commercial names may also
98 be provided for other products (test kits, reagents that are available from a single supplier or
99 types of filter, etc.), depending on the perceived usefulness for analysts. These commercial names
100 are transferred to the EDQM Knowledge Database after the monograph is adopted and are not
101 published in the Ph. Eur.

102 I.7 REFERENCE STANDARDS

103 The general policy for Ph. Eur. reference standards is provided for information purposes in general
104 chapter 5.12. *Reference standards*. In addition to procuring candidates and establishing reference
105 standards, the EDQM is responsible for storing and distributing reference standards. When
106 candidate reference standards, notably impurity standards, are available only in limited quantities,
107 the amount prescribed for the preparation of solutions is kept to a minimum. For the same reason,
108 when a reference standard is introduced in a monograph or general chapter, consideration is to be
109 given to its long-term sustainability. Before a monograph is published in *Pharmeuropa*, the required
110 quantities of candidates should be supplied to the EDQM, who will advise on the best strategy for
111 reference standards, while optimising the use of substances that are available in limited quantities
112 (e.g. preparation of a spiked substance, use of a “dirty sample” or supply of the impurity alone).
113 The EDQM aims to have the reference standards available at the date of publication of the
114 monograph or, if this is not possible, by the time of implementation at the very latest. Having a
115 sufficient amount of a suitable candidate reference available at the EDQM before the monograph is
116 adopted is a pre-requisite for achieving this goal.

117 For infrared (IR) identification, preference is given to chemical reference substances (CRS) over
118 reference spectra, except in special cases (e.g. when it is difficult to procure). In exceptional cases,
119 for monographs on narcotic/psychotropic substances, the relevant GoE may decide to describe both
120 a CRS and a reference spectrum in the identification test.

121 **II. MONOGRAPHS ON SUBSTANCES FOR PHARMACEUTICAL USE ¹**

122 Monographs are based on the specifications for substances used in medicinal products approved in
123 member states. When a monograph is added to the work programme, enquiries are made by the
124 EDQM to identify manufacturers of such substances and all data received are taken into account
125 for the preparation of the monograph. Stakeholders are invited to collaborate on the elaboration of
126 the monograph when the topic is added to the work programme so that their approved
127 specifications can be taken in account.

128 Prior to the elaboration of a monograph, it is essential to gather as much information as possible
129 on the substance in question. In particular, it is necessary to ascertain:

- 130 • whether the substance is of natural, synthetic or semi-synthetic origin;
- 131 • whether the substance is a mixture or a single entity;
- 132 • whether there are different crystalline forms, since the properties of the substance may
133 vary in accordance with this parameter;
- 134 • whether both an enantiomer as well as the racemate or other mixtures of enantiomers are
135 available;
- 136 • whether substances with a different degree of hydration (defined or variable) are available;
- 137 • whether the substance is available as a solvate (excluding hydrates);
- 138 • whether different entities (acid, base, salt, etc.) are available;
- 139 • where appropriate, the method(s) of preparation.

141 The Ph. Eur. and other relevant documents on the state of work must be consulted to see if
142 monographs on similar substances exist or are being elaborated. If this is the case, it is important to
143 ensure that similar monographs follow the same approach unless there are good reasons to deviate
144 from it (e.g. developments in analytical techniques or different specifications).

145 When a substance exists both in a water-free form and in the form of one or more hydrates with
146 different water contents, and if all these forms are used, they are normally treated as individual
147 substances requiring separate monographs. The same rule applies for other solvates.

148 Substances that are to be described in a monograph may be members of a group of very
149 similar substances (family). This holds true especially for excipients such as macrogols. In such
150 cases, a master monograph (family monograph) is to be drafted clearly stating the attributes
151 common to all members of the family and that can be used to identify single members of the family.

152 Most active substances and excipients are subject to the provisions of the general monograph

¹ Where appropriate, the statements in this section apply to monographs on medicinal products, otherwise see other relevant technical guides such as the [Technical Guide for the elaboration of monographs on medicinal products containing chemically defined active substances](#)

153 *Substances for pharmaceutical use (2034).*

154 II.1 TITLE

155 The International Nonproprietary Name (INN) established by the World Health Organization
156 (WHO) should be used wherever it is available, unless there are justifiable reasons for not doing
157 so; it is supplemented as appropriate by the name of the anion or cation and by the degree of
158 hydration. Anions and cations are indicated as “mono-, di-, tri-, etc.”, as appropriate.

159 The following rules apply for the degree of hydration:

- 160 • In the case of a well-defined hydrate, “hemi-, mono-, 1.5-, di-, tri-, etc. hydrate” is added to
161 the title, whereas if the monograph covers more than one degree of hydration, the general
162 term “hydrate” is used. In the latter case, a sentence is added to the DEFINITION section of
163 the monograph (see part II.3). For monographs published prior to the 9th Edition of the
164 Ph. Eur., retrospective introduction of the degree of hydration in titles would only be made
165 after careful consideration.
- 166 • Since the 9th Edition of the Ph. Eur., monographs referring to “anhydrous” substances no
167 longer specify this in their title, with the exception of a few monographs where this
168 information has recognised added value and/or is used in common scientific language (e.g.
169 *Ethanol, anhydrous*).
- 170 • No mention is added to the title of monographs covering substances that can be either water-
171 free or with a defined or variable degree of hydration. This supplementary information is
172 provided in the DEFINITION section of the monographs (see part II.3).

173 Where a substance is used in member states in approved medicinal products for veterinary use
174 only, “for veterinary use” is included in the title.

175 II.2 FORMULAE, MASSES AND CAS NUMBERS

176 The chemical structure must be ascertained with the greatest possible care in order to establish the
177 exact:

- 178 • graphic formula;
- 179 • empirical formula and relative molecular mass. The latter is calculated as follows:
180 first, the relative atomic masses, or multiples thereof, are added together using all the
181 figures of the International Table of Relative Atomic Masses; the total is then rounded off
182 according to general rules and given to four significant figures if the molecular mass is
183 below 600 or otherwise to three significant figures;
- 184 • the CAS number, included for information, wherever appropriate;
- 185 • chemical name (mentioned in the DEFINITION section of the monograph). This involves in
186 particular:
 - 187 ○ investigating the possible existence of isomers so as to be able to specify which
188 isomer is used or, failing that, to state that the product is a mixture of isomers;
 - 189 ○ in the case of a stereoisomer, it is not sufficient to take into account only the direction
190 of the optical rotation. The absolute configuration is given by the appropriate IUPAC
191 nomenclature at the asymmetrical centre(s), e.g. *R/S* system or any other appropriate

- 192 system, such as for carbohydrates and amino acids;
193 ○ ascertaining the state of hydration so as to distinguish clearly between the well-
194 defined hydrates (mono-, di-, tri-, etc. hydrate) and the products that contain variable
195 quantities of water. In the latter case, the term “x-hydrate” is introduced in the
196 chemical name.

197 II.3 DEFINITION

198 If the substance contains a variable quantity of water, or refers to both water-free and hydrate
199 forms, a sentence is added to the DEFINITION section to explain the exact scope of the monograph.

200 Some chemical substances, particularly those obtained from raw materials of natural origin and
201 substances produced by fermentation may not be easily separated from certain related substances
202 (e.g. quinine salts). These may be treated as:

- 203 • a chemical product when obtained in a very pure state and when they can be assayed by
204 a physico-chemical method;
- 205 • a substance accompanied by a certain proportion of related substances, giving an exact
206 definition of the main component only (e.g. neomycin);
- 207 • a mixture of several components, sometimes difficult to define, where an overall
208 description may suffice (e.g. nystatin).

209
210 Where applicable, the origin of the substance must be specified (name and strain of the organism
211 from which the substance is derived). Where applicable, the monograph indicates that the substance
212 is semi-synthetic and is derived from a fermentation product [to clarify application of the general
213 monograph *Substances for pharmaceutical use (2034)*].

214 II.3.1. Combinations

215 In medicinal products, more or less well-defined chemical combinations (e.g. theophylline-
216 ethylenediamine) or even mixtures are sometimes used. In such cases, it is necessary to
217 specify each component of the combination or mixture precisely, with its chemical structure and
218 the proportion in which it is present.

219 II.3.2. Content

220 The substance described by a monograph is never a wholly pure substance but contains a limited
221 proportion of impurities. The content therefore forms an important part of the definition.

222 The content of the active substance must be within specified assay limits. These limits are
223 established taking into account the following:

- 224 • the manufacturing process, which determines the degree of purity that may be reasonably
225 achieved;
- 226 • the reproducibility and accuracy of the analytical procedure;
- 227 • current batch data of at least 10 production batches at release;
- 228 • the evaluation of stability data;
- 229 • a sufficient number of experimental results obtained on several batches (at least three),

- 230 if possible, of different origins and ages.
231
- 232 For a non-specific assay by titrimetry, the limits are set according to the table provided in part
233 III.3.7 (i.e. usually 99.0-101.0%). Some monographs still include an assay by UV-Vis
234 spectrophotometry, for which wider limits are generally set.
- 235 For a specific assay using a separation technique (for example, liquid or gas chromatography), the
236 upper assay limit is normally 102.0%; the lower assay limit will take account of the impurities
237 present based on the available batch/stability data and approved specifications. It may therefore be
238 lower than 98.0%.
- 239 When the substance to be examined contains only impurities that do not interfere with the assay,
240 or when it contains only a very low proportion of impurities interfering with the assay, the results
241 of the assay can be used directly. It will then be stated that: “[*the substance*] contains not less than
242 *x per cent and not more than the equivalent of y per cent* (at least 100.5%, but often a little more)
243 *of [chemical definition of the pure product]*”. The content of the substance is usually expressed
244 with reference to the anhydrous or dried substance. According to the general monograph
245 *Substances for pharmaceutical use (2034)*, the content of residual solvent is taken into account for
246 calculation of the assay content of the substance, therefore no reference is made in the DEFINITION
247 section of the individual monograph.
- 248 In cases where the water content is high (e.g. disodium phosphate dodecahydrate), content limits
249 may be expressed with reference to the hydrate form of the substance, taking into account the
250 molecular mass of the hydrate form (only for well-defined hydrates) or with reference to the
251 substance on the anhydrous/dried basis in combination with determination of water content/loss
252 on drying.
- 253 When the substance to be examined contains a relatively large proportion (a few %) of impurities
254 that are determined at the same time as the active substance, appropriate wording is to be used (for
255 instance, in the case of quinine salts: “*x per cent of total alkaloid salts, expressed as quinine*
256 *salts*”).
- 257 In exceptional cases, reference is made to only a part of the molecule or to an element (e.g. assay
258 of magnesium oxide in light magnesium carbonate or assay of magnesium in magnesium stearate).
- 259 In the case of antibiotics determined by microbiological assays, the active substance content is
260 expressed in International Units, where these exist, and only a minimum value is given.
- 261 See also part II.8.

262 II.4 PRODUCTION

263 Statements in the PRODUCTION section draw attention to particular aspects of the manufacturing
264 process, but these are not necessarily exhaustive. They constitute mandatory requirements for
265 manufacturers, unless otherwise stated. See the *General Notices* for further information.

266 II.5 CHARACTERS

267 As defined in the *General Notices*, statements in the CHARACTERS section of a monograph are not

268 to be interpreted in a strict sense and are not regarded as requirements. The principal items that may
269 be referred to under this section are outlined below.

270 II.5.1. Appearance

271 This description will typically cover colour and physical form. The term “white” is not used
272 without qualification since, if viewed against a standard white material, very few pharmaceutical
273 materials will appear truly white. Of course, it is not intended that such a comparison be made, but
274 experience has shown that some users of the Ph. Eur. may insist on it as part of a purchasing
275 contract. The term “white or almost white” is used instead. Where positive colours are to be
276 described, this is done in terms of primary colours or combinations of primary colours.

277 II.5.2. Taste

278 Taste is not to be taken into consideration.

279 II.5.3. Odour

280 In general, no reference is made to odour, especially for materials that would constitute a hazard if
281 inhaled. Mention of odour in other cases must be justified.

282 II.5.4. Solubility

283 For solid materials, all solubilities are quoted in the general terms defined in general chapter
284 5.11. *Characters section in monographs*, which also includes a procedure recommended for the
285 estimation of solubility. For liquid materials, it is stated whether they are miscible or not. Solvents
286 quoted are normally restricted to water, an alcohol and a lipophilic solvent (e.g. water, ethanol (96
287 per cent) or anhydrous ethanol, heptane). Solubilities in chloroform and ether are not mentioned
288 and the use of hexane is discouraged. In exceptional cases, the solubility of different samples of a
289 material may vary considerably, despite their composition still being within the limits set by the
290 monograph. More than one solubility class is therefore given to cover the solubilities in the solvents
291 affected (e.g. “*sparingly soluble to soluble in...*”). In some cases, it may be useful to specify
292 solubility in alkalis or acids and, especially for materials that are very insoluble in the above-
293 mentioned solvents, a special solvent may be indicated (e.g. dimethylformamide or dimethyl
294 sulfoxide). It is not necessary to specify the solubility in every solvent that is used in performing
295 the tests of the monograph itself. The solubilities or miscibilities in other solvents with which the
296 material is often combined in practice (e.g. fatty oils) may also be mentioned.

297 II.5.5. Stability factors

298 Evidence of instability due to exposure to air, light and moisture is to be given (e.g. physostigmine
299 sulfate turns red when exposed to air and light). Any such statement in the CHARACTERS section is
300 given separately from the description of a pharmacopoeial material.

301 II.5.6. Hygroscopicity

302 A pragmatic method recommended for the determination of the tendency of a substance to take

303 up atmospheric water (rather than a true determination of hygroscopicity) is given in general chapter
304 5.11. *Characters section in monographs*. Some substances are hygroscopic or deliquescent, which
305 results in difficulties for the analyst during weighing procedures. In such cases, this is indicated
306 using the terminology defined in general chapter 5.11 and serves as an alert that the analyst should
307 take necessary precautions when handling the substance. When a substance is hygroscopic, a
308 STORAGE section is added (“*in an airtight container*”).

309 II.5.7. Solid-state properties

310 Solid-state properties include crystallinity, polymorphism, density of solids, particle size of solids
311 and specific surface area of solids. Solid-state properties, particularly polymorphism and
312 pseudopolymorphism, may have an effect on the bioavailability of the substance and for the
313 production of the medicinal product. General chapter 5.9. *Polymorphism* should be consulted.

314 A procedure recommended for the determination of crystallinity is given in general chapter
315 5.11. *Characters section in monographs*.

316 Solid-state properties of excipients that are relevant for functionality may be covered in the
317 FUNCTIONALITY-RELATED CHARACTERISTICS section (see part II.12).

318 The inclusion of a statement of polymorphism in a monograph is intended to alert users to the
319 need to evaluate this phenomenon during the development of a medicinal product, see also part
320 on infrared absorption spectrophotometry (II.6.3).

321 Two cases are to be distinguished when polymorphism is known to exist:

- 322 • usually, the monograph does not exclude any of the possible crystalline forms;
- 323 • exceptionally, if the substance is only used in solid dosage forms and one form has
324 been preferred for bioavailability reasons or by virtue of having a better safety/efficacy
325 profile, then the monograph may be limited to that form by adding the following sentence:
326 “*Preparation: examine the substances without prior treatment*”. The techniques required
327 to identify the form are included in the IDENTIFICATION section.

328 II.5.8. Other characteristics

329 Other physical characteristics that may be useful for information purposes, but which are not
330 sufficiently precise to be defined under the IDENTIFICATION or TESTS sections, may be stated in the
331 CHARACTERS section. This would typically apply to a melting point that is insufficiently precise to
332 allow a range to be quoted; if a range can be quoted, the melting point may be included in the
333 IDENTIFICATION section. Any potential for decomposition must be stated. Other general
334 characteristics that may need to be stated in the CHARACTERS section include an indication of
335 direction of optical rotation in a particular solvent or, in the case of radioactive materials, a statement
336 of the half-life of the radionuclide and the type of radiation it emits.

337 II.5.9. Behaviour in solution

338 In cases where it is known that degradation may occur in solution, a warning is included in the text.
339 In this context:

- 340 • “*Freshly prepared solution*” means that the solution is prepared each time the test/assay is

341 to be carried out and is used within 24 h;

- 342 • “*Immediately before use*” indicates that the stability of the corresponding solution(s) was
343 found to be critical during the elaboration of the text. The time between preparation and use
344 must be kept to a minimum.

345 Furthermore, and where applicable in the tests, it should be indicated that the solutions are to be
346 stored at a certain temperature and kept at a certain temperature in an autosampler.

347 II.6 IDENTIFICATION

348 II.6.1. General

349 The purpose of the IDENTIFICATION section of a monograph is to provide confirmation of the identity
350 of the substance in question. Identification according to the Ph. Eur. is thus generally much more
351 limited in scope than the identification and/or structural elucidation of an unknown substance or
352 the determination of the composition of an unknown mixture. The task of identifying a material is
353 not to be confused with the assessment of its purity or the determination of its strength, although
354 ultimately all three aspects are complementary.

355 Thus, when taken together, the physical and/or chemical tests and reactions included in the
356 IDENTIFICATION section ensure, as far as possible, specificity. The specificity of the identification
357 should be such that active substances and excipients exhibiting similar structures are distinguished
358 from each other. The tests must not be too sensitive (false reactions caused by the presence of
359 tolerated impurities are to be avoided) and they must not require more experimental effort than
360 necessary in order to differentiate the substance in question from other commercially available
361 pharmaceutical substances. The time needed to perform a test is also taken into account when
362 considering experimental effort.

363 Typically, a single set of identification tests is given; however, some monographs may give two
364 or more alternative sets of identification tests that are equivalent and may be used independently.
365 The intended purpose of the alternative sets of tests is the same (e.g. verification that the correct
366 enantiomer is present).

367 In addition, for some substances used in community pharmacies or hospital pharmacies, a second
368 series of identification tests is given (see part II.6.2). This second identification series should not be
369 confused with the alternative sets mentioned above.

370 Some of the purity tests in a monograph may also be suitable for identification purposes, possibly
371 in a modified form. A system of cross-references to the TESTS or ASSAY section can be used. This is
372 particularly relevant if distinction between closely related materials depends on properties that
373 are also parameters in purity or composition control (water content of different hydrates, chiral
374 chromatography of enantiomers or optical rotation, viscosity of chain-length homologues of a
375 polymer, etc.). Cross-reference to the ASSAY section often consists of identification via comparison
376 of retention times and peak sizes (areas) of the substance to be examined with those of a reference
377 substance. Acceptance criteria (e.g. permitted deviations in retention times) are not typically given
378 in the monograph but should be defined in the internal quality management systems on the user’s
379 site. The IDENTIFICATION section in the monograph suffices to identify the article even if it includes
380 cross-references to other sections.

381 The monograph of a substance must not be treated in isolation. When an identification series is
382 being investigated, it is desirable that other similar substances, regardless of whether they are the
383 subject of pharmacopoeial monographs, are examined at the same time to ensure that a particular
384 combination of tests within a series will successfully distinguish between two similar substances.

385 In the case of a family monograph, identification of the type of substances may be supplemented
386 by non-specific but discriminating tests to identify individual members of the family.

387 Examples of methods of identification are listed below and detailed guidance concerning some
388 of them is given throughout part II.6.

389 Instrumental methods:

- 390 • Spectroscopic analysis, such as recording of infrared (IR) or nuclear magnetic resonance
391 (NMR) spectra;
- 392 • Chromatographic examination by means of gas chromatography (GC) or liquid
393 chromatography (LC).

394

395 Other methods may be used if appropriate:

- 396 • Determination of physical constants such as melting point, freezing point, boiling
397 point, specific optical rotation, ultraviolet spectrum, specific absorbance, relative density,
398 refractive index and viscosity.
- 399 • Chemical reactions such as colour or precipitation reactions (including formation of
400 derivatives or degradation products, which may subsequently be subjected to physical
401 examination) and determination of chemical values (saponification, ester, hydroxyl
402 and iodine values).
- 403 • Chromatographic examination by thin-layer chromatography (TLC) or high-performance
404 thin-layer chromatography (HPTLC).

405

406 II.6.2. First and second identification series

407 Some monographs have subdivisions (i.e. series) entitled “First identification” and “Second
408 identification”.

409 The test(s) that constitute the “First identification” may be used in all circumstances. Second
410 identification testing is only intended to be used by community pharmacies or hospital pharmacies
411 that compound unlicensed pharmaceutical preparations provided it can be demonstrated that the
412 substance is fully traceable to a batch certified to comply with all the requirements of the monograph
413 and that this is documented in a certificate of analysis.

414 The implementation of the tests in the second identification series is subject to national regulation.
415 A second identification series is not intended to be applied by manufacturers for quality control
416 purposes for approved medicinal products (it is implied that good manufacturing practice is
417 applied).

418 The aim of the tests in the second identification series is to confirm the identity of the substance
419 using affordable analytical instrumentation and accessible implementation methods, rather than
420 relying on complex technologies. Wherever possible, it is recommended to use the principles of
421 mixed melting point, refractive index and, as required, miniature TLC complemented by wet-

422 chemical testing. Second identification tests should provide the user with at least two results that
 423 confirm the identity of the substance. These results can either be obtained by two independent tests
 424 or by a single test that provides two or more pieces of information about the identity of the substance.
 425 The combination of refractive index with relative density is an example of the former; a TLC with
 426 the application of a detection reagent is an example of the latter.

427 In order to introduce a second identification series, it should be assessed on a case-by-case basis
 428 whether concrete knowledge is available that the substance is used:

- 429 • in a magisterial formulary or a pharmacopoeia; or
- 430 • in formulations made for special target groups or distinct medicinal indications where no
 431 licensed product exists; or
- 432 • for pharmacy compounding (e.g. when they are offered for this purpose by suppliers).

433 II.6.3. Infrared absorption spectrophotometry

434 This is generally considered to be a satisfactory single method for verifying the identity of non-
 435 ionised organic substances other than salts of organic acids or bases. This analytical technique
 436 always requires the use of a reference substance or a reference spectrum. Reference substances are
 437 preferred to reference spectra; the latter are used where there are practical difficulties with providing
 438 a reference substance (e.g. in cases of particular toxicity or instability).

439 Organic salts of organic substances and some inorganic salts of organic substances (e.g. phosphates
 440 and sulfates) can readily be distinguished from each other. In the case of sulfates, however, it
 441 is necessary to extend the usual range of recording from 4000-650 cm⁻¹ to 4000-400 cm⁻¹.

442 Since monographs do not typically prescribe a specific mode, all modes described in general chapter
 443 2.2.24 (e.g. ATR mode, transmission mode) may be used. The type of sample preparation (disk,
 444 halide salt plate, mull, etc.) is not specified unless this has been found to be necessary during
 445 the elaboration of the monograph in order to obtain a satisfactory spectrum.

446 In certain cases, the infrared spectrum alone is not sufficient to confirm the identity of a substance
 447 and other tests must also be performed.

- 448 • *Salts of organic acids or bases*: for several ions or groups that form part of an organic
 449 substance (counter-ion), more than one identification test may be described in general chapter
 450 2.3.1. However, it is usually only necessary to use one of them.
- 451 • *Chemically related substances*: in the case of substances closely related to the substance to
 452 be examined where variations in the spectra are not considered sufficient for unambiguous
 453 identification, the infrared identification test is accompanied by another simple test (e.g.
 454 melting point or TLC with the use of a reference substance).
- 455 • *Polymorphism*: the sentence “*It shows polymorphism*” is added only when more than one
 456 crystalline forms is used in approved medicinal products and the different forms are available
 457 for testing.

458 General chapter 2.2.24. *Absorption spectrophotometry, infrared* allows for “recrystallisation”
 459 before recording of the spectrum.

460 If a monograph mentions polymorphism, a method for “recrystallisation” is described, unless
 461 the intention is to limit the scope of the monograph to the crystalline form represented by the
 462 chemical reference substance, in which case the monograph indicates that the spectrum is
 463 recorded “without recrystallisation”.

464 In exceptional cases, if the monograph describes a specific crystalline form or forms and
465 when the IR spectrum is not characteristic, an additional test is introduced.

- 466 • *Optical isomers*: to identify a particular enantiomer or a racemate, see part II.6.6.

467 II.6.4. Absorption spectrophotometry (ultraviolet and visible)

468 Unlike IR spectroscopy, this method is usually not specific enough for identification purposes
469 unless the absorption curve exhibits several maxima and minima, unusually strong or weak regions
470 of absorption, etc.

471 Reference substances are not generally used for identification. The UV-Vis spectrum of a substance
472 is therefore rarely used as the sole identification criterion.

473 The concentration of the solution to be examined is such that the absorbance preferably lies between
474 0.5 and 1.5, measured in a 1 cm cell.

475 The range of wavelengths to be explored must be stated; it does not typically extend to the region
476 where end-absorption and solvent interference may be expected. The wavelengths of sharp
477 maxima and minima are indicated by a single number, signifying ± 2 nm, while for broader bands
478 a range is given. When it is considered necessary to mention the wavelength of shoulders, the term
479 “about” may be used.

480 Specific absorbances are also given as a range (usually $\pm 5\%$) in order to cover variations in
481 content of absorbing substance and experimental error. It is to be noted that the instrument
482 tolerance for absorbance is ± 0.010 or 1%, whichever is greater, which means that the deviation due
483 to this source of variability will depend on the absolute levels of absorbance. Furthermore, the
484 content of absorbing substance will vary with the permitted content of water (or other solvents);
485 when the latter does not exceed 1% or is within well-defined limits, it will usually be adequate to
486 calculate the specific absorbance for the substance “as is” and to set the limits accordingly. When
487 more than a single maximum is present in the spectrum, the ratio(s) between their absorbances can
488 be substituted for the individual specific absorbances, providing the ratio is less than or equal to 5,
489 thus avoiding having to correct the absorbances for the solvent content of the substance.

490 Care must be taken in the choice of solvents and solvent purity prescribed for UV
491 spectrophotometry in order to avoid the presence of impurities, which may influence the absorbance
492 of the substances to be examined.

493 In certain cases, the resolution of the instrument can be a critical factor in observing the required
494 spectral features (e.g. benzenoid-type spectra showing a fine structure). The minimum resolution
495 required may be indicated in the monograph. In order to determine this figure, the slit-width setting
496 is deliberately varied to the point where the spectrum obtained is just adequate for the intended
497 purpose. The resolution corresponding to this setting is then experimentally defined on the basis of
498 an absorbance ratio for a 0.02% V/V solution of *toluene R* in *hexane R* or preferably *heptane R* as
499 prescribed in general chapter 2.2.25. *Absorption spectrophotometry ultraviolet and visible*. The
500 minimum ratio is indicated in the monograph to two significant figures.

501 Table 3 indicates the approximate relationships to be expected between the spectral slit width and
502 the absorbance ratio.

503 Table 3 – Resolution of spectrophotometers according to the slit width

Slit width (nm)	Ratio $A_{\max 269 \text{ nm}}/A_{\max 266 \text{ nm}}$
0.25	2.3
0.5	2.2
1.0	2.0
2.0	1.4
3.0	1.1
4.0	1.0

504

505 II.6.5. Melting point, freezing point and boiling point

506 These physical constants are of value to identification only if they are well defined and their
507 determination is not accompanied by destruction to a degree that renders them extremely dependent
508 on the actual mode of operation. The possible existence of polymorphism must also be taken
509 into account; differences in the melting point must be indicated even when given in the CHARACTERS
510 section. In exceptional cases, when the distinction of a specific crystalline form is necessary,
511 determination of the melting point can aid in excluding the unwanted form(s).

512 However, it should be kept in mind that an apparent melting point may be observed: a solid-solid
513 polymorphic transition may take place during testing and the melting point of the resultant form is
514 measured.

515 For the first identification, neither the melting point alone nor the addition of a chemical reaction is
516 sufficient to confirm the identity of a substance. However, combining one of these two tests with
517 another identification test such as IR will often suffice. For the second identification, please refer
518 to part II.6.2.

519 The melting point determined by the capillary method is defined in the Ph. Eur. (see general
520 chapter 2.2.14. *Melting point – capillary method*) as the last particle melting point (i.e. clear point
521 or liquefaction point). It must not be confused with the melting interval even though both are given
522 as a range.

523 II.6.6. Identification of substances that have one or more stereocentre(s)

524 When only the racemate monograph is available in the Ph. Eur., the angle of rotation will be given
525 in the TESTS section, provided the specific optical rotation of the chiral form is known and is of
526 sufficient magnitude to provide a meaningful test for racemic character.

527 When a monograph describes an enantiomer only, the monograph contains a test for enantiomeric
528 purity in the TESTS section and a cross-reference in the IDENTIFICATION section. If this is not possible,
529 a test for specific optical rotation is added in the TESTS section of the monograph and is cross-
530 referenced in the IDENTIFICATION section.

531 If monographs exist for both the racemate and the enantiomer, the monograph of the racemate
532 contains an optical rotation test in the TESTS section and a cross-reference in the IDENTIFICATION
533 section. The use of an optical rotation test is discouraged in other situations due to its lack of
534 specificity.

535 II.6.7. Thin-layer chromatography

536 This identification method requires the use of reference substances. Selectivity may be improved by
537 combining TLC with chemical reactions *in situ* i.e. by employing appropriate spray or dipping
538 reagents, in which case the same or a similar reaction is not to be repeated on a test-tube scale.

539 Although it is very important to ensure the separation of a critical pair in a related substances test,
540 this plays a minor role in an identification test. The separation of a critical pair in the individual
541 identification tests is no longer required but the separation of a critical pair in the TESTS section is
542 maintained. However, during development and validation, separation of the substance from similar
543 substances must be demonstrated.

544 A chromatographic separation test for TLC plates is usually described in general chapter
545 4.1.1. *Reagents* to verify the performance of the plate type concerned. The test is intended to be a
546 quality control procedure, carried out periodically by the TLC plate user. It is clear that such a
547 general procedure is not appropriate for every thin-layer separation problem and that the description
548 of a separation criterion might still be necessary to ensure the identification of the substance. In
549 these exceptional cases, a separation criterion is described in the IDENTIFICATION section.

550 A TLC system applied to purity testing in a monograph is preferred for identification when suitable.
551 In this case, the concentration of the solution to be examined and the corresponding reference
552 solution are generally reduced so that 5-20 µg of each is deposited on the plate or sheet. It may
553 also be necessary to switch to a more discriminating detection system.

554 For more technical requirements on these chromatographic methods, see part II.7.8.

555 II.6.8. Gas chromatography and liquid chromatography

556 The basic principles mentioned under thin-layer identification apply, taking account of the
557 differences between the two. Gas and liquid chromatography are increasingly used for
558 identification purposes; where they are, the IDENTIFICATION section simply refers to a test or assay
559 that applies the method elsewhere in the monograph. These methods are used only if there is no
560 suitable alternative; they are not used as the only identification test.

561 For more technical requirements on gas and liquid chromatography see part II.7.8.

562 II.6.9. Chemical reactions

563 Several commonly applied identification reactions of a chemical nature are included amongst the
564 general chapters of the Ph. Eur., and these are to be used whenever appropriate. Where several
565 reactions for an ion or group are given in general chapter 2.3.1. *Identification reactions of ions and*
566 *functional groups*, it is normally necessary to prescribe only one in the monograph. Note the need
567 to specify the amount of material, or solution of it, to be taken for the identification test in question.
568 The same holds true for tests that have to be described in full in the monograph. Identification
569 reactions using toxic reagents (e.g. REACH reagents) are being slowly phased out; special care
570 should be taken when choosing a chemical reaction to be added to a monograph.

571 Identification criteria that call for the recognition of an odour or a taste are to be avoided.

572 Each chemical reaction chosen must demonstrate the presence of a different part of the molecule to

573 be identified.

574 To differentiate substances within a group (family) which differ either by the extent of condensation
575 or by the length of the hydrocarbon chain (e.g. fatty acids), a cross-reference must be added to the
576 appropriate purity test(s) where values are determined (e.g. iodine value, saponification value, etc.).

577 II.7 TESTS

578 II.7.1. General

579 The main purpose of the TESTS section is to limit impurities in chemical substances. General chapter
580 *5.10. Control of impurities in substances for pharmaceutical use* gives details of the policy to be
581 applied.

582 While the monograph must ensure adequate purity in the interests of public health, it is not the aim
583 of the Ph. Eur. to impose excessive requirements that restrict unnecessarily the ability of
584 manufacturers to produce compliant products.

585 In the interests of transparency, information is included wherever possible on:

- 586 - the impurities controlled by a test;
- 587 - the approximate equivalent (percentage, ppm, etc.) of the prescribed limit in terms of the
588 defined impurities or class of impurities.

589 In addition to approved specifications in marketing authorisations, acceptance criteria and limits are
590 set on the basis of analytical data at hand (i.e. batch results provided by manufacturers and data
591 produced during monograph elaboration by the testing laboratories). In order to define limits for
592 tests (loss on drying, residual water, etc.), the “3-sigma” rule may be used. In a normal distribution,
593 99.7% of values lie within three standard deviations of the mean. A minimum of 10 test results,
594 obtained from one source, must be available to calculate the mean. However, it should be noted that
595 the empirical rule is not applied systematically. This is especially true for the related substances
596 test, where impurity limits should reflect more closely their real content in substances used in
597 approved medicinal products.

598
599 *Example 1: Determination of specification for water content (2.5.12)*

600 → *Batch data provided by a manufacturer: 10 batches*

601 → *Min. value: 3.2%, max. value: 5.4%*

602 → *Mean + 3 sigma = 6.1%*

603 *Conclusion: The limit for water is set at 6.1% according to the 3-sigma rule.*

604
605 *Example 2: Determination of specification for impurity X limit*

606 → *Batch data for level of impurity X provided by a manufacturer: 57 batches*

607 → *52 batches around or less 0.05%, 4 batches about 0.08%, 1 batch 0.09%,*

608 → *Mean + 3 sigma = 0.11%*

609 *Conclusion: The 3-sigma rule is not applied. The limit for impurity X is set at 0.10%, based on batch*
610 *data.*

611

612 Certain tests may apply to special grades (parenteral, dialysis solutions, etc.) or a test may have
613 a special limit for a particular use: this is indicated within the test.

614 II.7.2. Title of tests

615 Wherever possible, the title includes the impurity or class of impurities limited by the test
616 (Oxalic acid, Potassium, Copper, Chlorides, etc.). Non-specific tests carry a more general title
617 appropriately chosen from the standard terminology of the Ph. Eur. (Appearance of solution, pH,
618 Acidity or alkalinity, etc.) or a similar designation. Titles that merely refer to the methodology
619 employed in the test (e.g. Absorbance) are to be avoided wherever possible.

620 II.7.3. Solution S

621 A solution of the substance to be examined, designated “Solution S”, is prepared whenever this
622 can be used to perform more than one test (and/or identification).

623 If necessary, several solutions S, (designated S1, S2, etc.) may be prepared in various ways, each
624 being used for at least two tests.

625 For insoluble substances, solution S may be prepared by an extraction process.

626 The solvent used depends on the purpose of the tests and the solubility of the substance to be
627 examined and that of its potential impurities. It may be:

- 628 • water (usually):
 - 629 ○ *carbon dioxide-free water R* in cases where the presence of carbon dioxide can
 - 630 appreciably influence the outcome of a test, e.g. for pH or Acidity or alkalinity (see
 - 631 part II.7.5);
 - 632 ○ *distilled water R* if solution S is used in the tests for barium, calcium and sulfates;
 - 633 ○ *carbon dioxide-free water R* prepared from distilled water when both previous cases
 - 634 apply;
- 635 • a dilute acid or an alkaline solution;
- 636 • more rarely, other solvents (alcohols, tetrahydrofuran, etc.) that give solutions with a
- 637 narrower field of application than aqueous solutions.

638
639 The solvent must make it possible to carry out the specified tests, either directly or after suitable
640 dilutions explicitly specified in each test. The concentration is around 20-50 g/L, but may be lower
641 (e.g. 10 g/L) or higher (100 g/L, possibly more in exceptional cases). The quantity of solution S
642 prepared must be sufficient to carry out each of the tests for which it has been prepared and should
643 be adapted, if necessary, if the text is revised. If solution S is to be filtered, the loss on filtering
644 must be taken into account, and if the insoluble portion thus separated is to be used for another
645 test, this is clearly indicated.

646 While several tests may be carried out on the same portion of solution S, this is only done for
647 substances where there are good reasons to economise (expensive products or products whose use
648 is subject to restrictions) and this is then clearly indicated in the monograph.

649 Depending on the particular tests, the concentration of solution S is defined with varying levels of
650 accuracy:

- 651 • for “Appearance of solution”, “pH” and some identifications, an accuracy of 5-10% is
652 sufficient;
- 653 • for most limit tests, an accuracy of about 2% is appropriate;
- 654 • for some cases, such as the determination of specific optical rotation, specific
655 absorbance, various chemical values and, more generally, tests where the result is obtained
656 by calculation, a greater level of accuracy is needed.

657

658 The accuracy with which the concentration of solution S is defined is that required by the most
659 exacting test for which it is intended. The description of the preparation of solution S thus specifies:

- 660 • the quantity of substance to be examined with the required accuracy (see *General*
661 *Notices*);
- 662 • the volume, to one decimal place (10.0 mL, 25.0 mL, etc.) when the concentration must
663 be known to within less than 1%, without a decimal (10 mL, 25 mL, etc.) when a
664 lower accuracy is adequate.

665

666 II.7.4. Appearance of solution

667 This test makes it possible to ascertain the general purity of a substance through the detection of
668 impurities insoluble in the solvent selected, or of coloured impurities.

669 The “Appearance of solution” test is practically always prescribed for substances intended for
670 preparations for parenteral use. Apart from this, it is to be applied only if it yields useful information
671 about specific impurities.

672 It can comprise one or both of the following tests:

- 673 • *Clarity and degree of opalescence of liquids (2.2.1)*;
- 674 • *Degree of coloration of liquids (2.2.2)*.

675

676 The two tests are practically always carried out on identical solutions, usually solution S, but
677 they may be performed on different solutions.

678 The solvent employed is typically water but other solvents may be used depending on the solubility
679 of the substance to be examined.

680 When an organic solvent is used to prepare solution S, it may be necessary to ensure that the solvent
681 also complies with the test, especially where there is a very stringent requirement.

682 The more concentrated the solution the stricter the test. For very pure substances or those used in
683 high doses, the concentration chosen is 50-100 g/L, whereas for less pure substances or substances
684 administered in small doses the concentration is 10-20 g/L.

685 II.7.4.1. *Clarity and degree of opalescence (2.2.1)*

686 This test is mainly performed on colourless substances or those that give only slightly coloured
687 solutions in order to permit valid comparison with reference suspensions. Newer instruments with
688 ratio selection are capable of measuring coloured substances.

689 The quantity of solution required depends on the diameter of the comparison tubes used; it varies

690 from 7-20 mL for tubes with a diameter of 15-25 mm prescribed in the general chapter. It is
691 therefore necessary to take the larger volume into account.

692 Most often, the solution examined must be “clear” (as defined in the Ph. Eur.). However, in certain
693 cases (e.g. substances that are not intended to be used in solution), a more marked opalescence may
694 sometimes be permitted.

695 *II.7.4.2. Degree of coloration of liquids (2.2.2)*

696 This test applies to essentially colourless substances that contain, or may degrade to form, coloured
697 impurities that can be controlled by limiting the colour of solution of the substance. Three methods
698 are described in general chapter 2.2.2. *Degree of coloration of liquids*:

- 699 • Method I only requires 2 mL of solution but is seldom prescribed except for substances
700 that give highly coloured solutions;
- 701 • Method II, which is more discriminating and therefore more frequently used, requires the
702 larger volume of solution employed for the clarity test;
- 703 • Method III describes the instrumental determination of the coloration and provides more
704 objective data than the subjective viewing of colours by a small number of individuals.

705

706 The results given by these three methods are not necessarily the same, so the one to be used is
707 specified in the monograph.

708 At present, the specifications indicated in the Ph. Eur. are all based on visual determination and an
709 exact correlation between visual and instrumental results is not always possible, depending on the
710 ability of the analyst to differentiate between colour grades (visual method) and on the equipment
711 settings. Hence, when using chapter 2.2.2, the analyst is asked to report the results together with the
712 method used (I, II or III).

713 The solution is described as colourless when it is less coloured than reference solution B₉. When
714 the solution is slightly coloured, the appropriate reference solution is given. When the shade of
715 colour varies depending on the samples, two or more reference solutions of the same degree of
716 colour may be mentioned, or even only the degree of coloration without specifying the actual
717 colour.

718 For material intended for parenteral use and for highly coloured solutions, especially when the use
719 of Method I is contemplated, it is preferable to apply a limit of absorbance measured with a
720 spectrophotometer at a suitable wavelength (usually 400-450 nm). The concentration of the solution
721 and the limit of absorbance must be stated. The conditions and limit must be based on knowledge
722 of the absorbance curve in the range of 400-450 nm and on results obtained with appropriate
723 samples, including stored and degraded samples, as necessary.

724 *II.7.5. pH and Acidity or alkalinity*

725 This test enables the limitation of acidic or alkaline impurities stemming from the method of
726 preparation or purification or arising from degradation (e.g. from inappropriate storage) of the
727 substance. The test may also be used to verify the stoichiometric composition of certain salts.

728 Two types of test for protolytic impurities are used in the Ph. Eur.: a semi-quantitative titration
729 experiment using indicators or electrometric methods to define the limits (the Acidity or alkalinity

730 test); or a pH measurement.

731 pH measurement is included if the material has buffering properties, otherwise a titrimetric
732 procedure is recommended.

733 The question of whether to prescribe an Acidity or alkalinity test or a pH measurement in a
734 pharmacopoeial monograph can be decided on the basis of an estimation of the buffering properties
735 of the material. To this end, a titration curve can be constructed for an aqueous solution (or, if
736 necessary, an extract) in the intended concentration (10-50 g/L) of a sample, preferably pure, of the
737 substance to be examined, using 0.01 M hydrochloric acid and 0.01 M sodium hydroxide,
738 respectively, and potentiometric pH measurement.

739 The inflexion point of the titration curve is the true pH of the solution and will, for a pure substance,
740 be at the point of intersection with the pH-axis. The measure of the buffering capacity of the solution
741 to be examined is the total shift in pH, (ΔpH), read from the titration curve as the result of adding
742 0.25 mL of 0.01 M sodium hydroxide to 10 mL of the solution and 0.25 mL of 0.01 M hydrochloric
743 acid to a separate 10 mL portion of the same solution. The buffering capacity is inversely
744 proportional to the ΔpH . For a sample that is not quite pure, carry out a parallel displacement of the
745 titration curve so that the true pH of the solution is on the pH-axis before the ΔpH is read from the
746 curve.

747 The magnitude of ΔpH of the solution to be examined determines the choice of method for the
748 limitation of protolytic impurities according to the following scheme. The classification is based
749 upon the observation that the colour change for most indicators takes place over a pH range of 2
750 units.

Class A	$\Delta\text{pH} > 4$	Acidity-alkalinity test using two appropriate indicators.
Class B	$4 > \Delta\text{pH} > 2$	Acidity-alkalinity test using a single appropriate indicator.
Class C	$2 > \Delta\text{pH} > 0.2$	Direct pH measurement.
Class D	$\Delta\text{pH} < 0.2$	The protolytic purity cannot be reasonably controlled. Substances that are salts consisting of ions with more than one acidic and/or basic function belong to this class and for these a pH measurement can contribute to ensuring the intended composition if the limits are sufficiently narrow.

751

752 It is evident that, by changing the concentration of the solution to be examined, the class of
753 buffering properties as set out above into which the substance will fall can be altered to some extent,
754 since the shape of the titration curve will also be modified as a result. The concentration range given
755 above is not to be exceeded, however, unless poor water solubility means that a more dilute solution
756 has to be used.

757 If a test for acidity-alkalinity cannot be performed with the use of indicators due to the coloration
758 of the solution to be examined or other complications, the limits are then controlled
759 electrometrically. If on the other hand, the addition of a standard acid or base leads to decomposition
760 or precipitation of the substance to be examined, it may be necessary to prescribe a pH test
761 regardless of the buffering properties.

762 If, for the reasons outlined above, a pH measurement has to be prescribed for solutions with little
763 or no buffering capacity, the solution to be examined is prepared with *carbon dioxide-free water R*.

764 Conversely, it is not necessary to use *carbon dioxide-free water R* when preparing solutions that
765 have sufficient buffering capacity to warrant a direct pH measurement because the required
766 accuracy, which seldom exceeds 1/10th of a pH unit, will not be affected. When an acidity
767 requirement corresponds to not more than 0.1 mL of 0.01 M sodium hydroxide per 10 mL of
768 solution to be examined, the solution must be prepared using *carbon dioxide-free water R*. These
769 considerations are to be borne in mind when prescribing the composition of solution S if it is to be
770 used in a test for protolytic impurities.

771 II.7.6. Optical rotation (2.2.7)

772 Measurements of the optical rotation of an article, though sometimes useful for identification
773 purposes, may be used as a purity test:

- 774 • either to assess the general purity of an optically active substance (a liquid or a solid in
775 solution), by calculating the “Specific optical rotation” (title of the test);
- 776 • or to limit the presence of optically active impurities in any “optically inactive” mixture
777 (racemate), provided that the specific optical rotation of the enantiomer at 589 nm is
778 sufficient to ensure adequate sensitivity. In this case, the optical rotation of the liquid or
779 of the solid in solution is measured under defined conditions (temperature, concentration,
780 path length) and the range normally given should be $- 0.10^\circ$ to $+ 0.10^\circ$ (covering the
781 substances that are not true racemates).

782
783 In monographs on a single active enantiomer (eutomer), chiral chromatography (“Enantiomeric
784 purity”) is preferred to control the other enantiomer (distomer) because specific optical rotation is
785 generally not specific enough for an appropriate control. On the other hand, an achiral
786 chromatographic procedure can generally be used to test for diastereoisomers.

787 Although the test is not suitable for highly coloured or opalescent solutions, filtration can
788 sometimes make the determination possible for opalescent solutions. Shortening the path length
789 can also help to measure particular samples (e.g. for some essential oils).

790 The following aspects are taken into account in describing the test:

- 791 • the solvent, which depends on the solubility of the substance to be examined and the
792 observed optical rotation in that solvent. In the case of non-aqueous solvents, their
793 purity and especially their water contents may need to be carefully defined;
- 794 • the quantity of substance to be used, determined with sufficient accuracy (generally
795 1%), and the volume to be prepared (given to one decimal place). Although the volume
796 depends on the apparatus used, 25.0 mL is usually prescribed because it rarely exceeds
797 that amount. The concentration of the solution must be high enough to give a reliable
798 reading of the angle of rotation;
- 799 • the degree of hydration or organic solvation of the substance (for the calculation of
800 the result);
- 801 • the result is the mean of at least five measurements when evaluated visually, with an
802 instrument allowing readings to the nearest 0.01°;
- 803 • measured angles of optical rotation are given to two decimal places;
- 804 • specific optical rotation values are given to two or three significant figures: values below
805 10 are given to two significant figures, while values of 10 and over are given to three

- 806 significant figures;
807 • composition limit for racemates.

808
809 The value of the specific optical rotation is calculated with reference to the dried or anhydrous
810 substance.

811 II.7.7. Absorption spectrophotometry (ultraviolet and visible) (2.2.25)

812 The absorption of electromagnetic radiation may be used in purity tests as a limit test for certain
813 impurities. The typical case is that of impurities that absorb in a region where the substance to
814 be examined is transparent, in which case the absorbance of a solution of the substance to be
815 examined is measured. This test may be performed in the following ways:

- 816 • by direct measurement on the solution, where the absorbance measured is a maximum
817 absorbance at a given wavelength or over a wavelength range;
818 • after carrying out a chemical reaction that forms, with the impurity, a substance that
819 absorbs at a wavelength where the substance to be examined is transparent, a maximum
820 value at the given wavelength being prescribed.

821
822 For measurements in the ultraviolet region, it is advisable to avoid measuring at wavelengths below
823 230 nm as more interferences and more stray light are observed in this region.

824 It is important to describe precisely the operational conditions to be observed, in particular the
825 preparation of solutions prepared by successive dilutions.

826 II.7.8. Related substances

827 The policy on control of impurities is described in general chapter 5.10. *Control of impurities in*
828 *substances for pharmaceutical use* and in the general monograph *Substances for pharmaceutical*
829 *use (2034)*. Monographs should be elaborated accordingly. Monographs are designed to take
830 account of substances used in approved medicinal products in member states and should provide
831 adequate control of all impurities occurring in these substances, insofar as the necessary information
832 and samples (substance and impurities) are available from the manufacturers. Such impurities are
833 controlled in a test for related substances and any other individual test for impurities (e.g.
834 “Impurity X” or “Enantiomeric purity”). Where the required information and samples are not
835 provided for a substance synthesised by a given method, the monograph will not necessarily cover
836 the corresponding impurity profile.

837 The provisions for related substances in the general monograph *Substances for pharmaceutical use*
838 *(2034)* and general chapter 5.10 apply to all active substances and excipients, unless otherwise
839 stated therein.

840 If an exception is to be made for a particular substance normally covered by these provisions, the
841 following statement is included in the specific monograph: “*The thresholds indicated under Related*
842 *substances (Table 2034.-1) in the general monograph Substances for pharmaceutical use (2034)*
843 *do not apply*”. It is recommended to provide the reason for the deviation in a footnote during the
844 *Pharmeuropa* stage. This explanation will be transferred to the EDQM Knowledge Database once
845 the monograph is published in the Ph. Eur.

846 Monographs should include acceptance criteria for:

- 847 • each specified impurity;
- 848 • unspecified impurities (previously referred to as “any other impurities”), normally set at
849 the identification threshold;
- 850 • the total of impurities.

851

852 Impurities to be controlled include intermediates and by-products of synthesis, co-extracted
853 substances in products of natural origin and degradation products. Monographs on organic
854 chemicals usually have a test entitled “Related substances” (or a test with equivalent purpose under
855 a different title), designed to control organic impurities. Where applicable, inorganic impurities are
856 usually covered by other tests. Residual solvents are covered by specific provisions [see below and
857 in general chapter 5.4. *Control of residual solvents* and the general monograph *Substances for
858 pharmaceutical use (2034)*].

859 **DNA-reactive (mutagenic) impurities.** *ICH guideline M7 on assessment and control of DNA*
860 *reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk*
861 *(EMA/CHMP/ICH/83812/2013)* entered into force on 1 January 2016.

862 The following pragmatic approach is in line with the ICH M7 guideline and should be followed
863 when elaborating or revising monographs related to substances for human use. A DNA-reactive
864 impurity is covered in the individual monograph **only** where there is study data demonstrating
865 mutagenicity of the impurity by a recognised toxicity test. The existence of structural alerts alone is
866 considered insufficient to trigger follow-up measures. Following a decision by the Ph. Eur.
867 Commission (November 2016), DNA-reactive impurities should be addressed in individual
868 monographs in:

- 869 - the PRODUCTION section, by a statement, when no specific test or limit is known to the GoE at
870 the time of elaboration/revision of a monograph or when the technique is so special that it is not
871 available to a majority of users;
- 872 - the TESTS section, when the analytical procedure and the limit are known and the technique is
873 widespread.

874 Additional information and requirements for specific types of DNA-reactive impurities is provided
875 in the general monograph *Substances for pharmaceutical use (2034)*.

876 If a new synthetic route is used that may give rise to different DNA-reactive impurities or to
877 higher levels of previously recognised ones, the evaluation by a Competent Authority should be
878 used as the basis for the impurity in question.

879 If an issue concerning a DNA-reactive impurity is raised by a Competent Authority (notably for
880 revision of a monograph or in comments on a *Pharmeuropa* draft), this will be dealt with on the
881 basis of data provided to the Ph. Eur. Commission by the Competent Authority.

882 **Control of impurities.** The most common and preferred method for controlling organic impurities
883 is LC; GC or CE may be the preferred method in some instances. Although there are still some
884 monographs that prescribe TLC, this technique should be reserved for controlling specific impurities
885 that cannot conveniently be controlled by LC or GC. Existing TLC tests that do not follow this
886 recommendation will be replaced gradually as soon as information on suitable LC or GC tests
887 becomes available.

888 Where the counter-ion of an active substance is formed from a lower organic acid, a test for related
889 substances of the organic moiety is usually not considered necessary (e.g. magnesium lactate used
890 as a source of magnesium).

891 Monographs frequently have to be designed to cover different impurity profiles because of the use
892 of different synthetic routes and purification procedures by manufacturers. The usual practice is
893 to include a general LC test, supplemented where necessary by other tests (LC, GC, CE, TLC or
894 other techniques) for specific impurities. However, it is becoming increasingly impractical in some
895 cases to design a single general test; in such cases, more than one general test is included and the
896 scope of the different tests is defined in the tests themselves with a cross-reference in the IMPURITIES
897 section.

898 Monographs cover a number of specified impurities listed in the IMPURITIES section. Specified
899 impurities are those that occur in current batches of the substances used in approved products and
900 for which an individual acceptance criterion is provided. Wherever feasible, monographs also have
901 an acceptance criterion for other impurities (at the identification threshold for the substance) and a
902 limit for the total of impurities (or a limit for the total of impurities other than a number of identified
903 specified impurities) above the reporting threshold. The acceptance criterion for specified
904 impurities may be set at the identification threshold for the substance.

905 The acceptance criteria for specified impurities take account of both:

- 906
- approved limits;
 - recent batch data and stability data, with the acceptance criteria being set to take account
908 of routine production conditions; data is provided by the manufacturer for typical batches
909 and verified experimentally during elaboration of the monograph on at least three batches.
- 910

911 If several approved limits exist, the highest is taken.

912 When a monograph describes the salt form of the substance, then, for the purpose of calculation and
913 specification setting and unless otherwise prescribed, the impurity is assumed to be present in the
914 same salt form.

915 All decisions on impurity acceptance criteria should be based on the real impurity content
916 (meaning after application of correction factors (CFs), where applicable) in representative batches
917 examined.

918 Impurities must be specified and located appropriately in the chromatogram if the reported batch
919 values for an impurity are:

- 920
- above the applicable limit for unspecified impurities before correction and cross this
921 limit downwards when corrected (overestimation, $CF < 1$); or
 - below the limit for unspecified impurities before correction and cross this limit upwards
923 when corrected (underestimation, $CF > 1$).
- 924

925 Usually, no correction factor will be given if the reported batch values for an impurity are below
926 the applicable limit for unspecified impurities before correction and below the reporting threshold
927 (disregard limit) after correction.

928 In any case, CFs between 0.8 and 1.25 (corresponding to response factors of 1.2-0.8) are not given
929 in monographs. Additional information on the indication of CFs is given in part II.7.8.2.b.

930 **Response and correction factors.** According to general chapter 2.2.46. *Chromatographic*
 931 *separation techniques*, the relative detector response factor (commonly referred to as the “response
 932 factor”) expresses the sensitivity of a detector for a given substance relative to a standard substance.
 933 The correction factor given in the monograph is the reciprocal value of the response factor.

934 The response factor can be determined by preparing solutions of defined concentrations of the
 935 impurity and the substance to be examined and measuring them by LC/UV at a given wavelength
 936 and flow rate. The concentration of the impurity and that of the substance to be examined should be
 937 of the same order of magnitude and the measurement should be carried out using a calibration curve
 938 determined at several points around the concentration which corresponds to the acceptance criterion
 939 of the impurity. For the calculation, the mean of the area ratios over the whole range of linearity or
 940 the ratio of the slopes of the respective linearity regression equations may be used. The response
 941 factor can be calculated using the following formula:

$$942 \quad RRF = \frac{A_i}{A_s} \times \frac{C_s}{C_i}$$

943 RRF = (relative) response factor;

944 A_i = area of the peak due to the impurity;

945 A_s = area of the peak due to the substance to be examined;

946 C_s = concentration of the substance to be examined in milligrams per millilitre;

947 C_i = concentration of the impurity in milligrams per millilitre.

948 It is also important to consider the form (base/acid or salt) of both the impurity and the substance to
 949 be examined used when determining the response factor and to apply an additional correction for
 950 the molecular mass ratio when they are present in different forms. This correction can be done by
 951 ensuring that C_i is expressed with respect to the same form as the substance to be examined (i.e. as
 952 base/acid or salt) provided the impurity can actually be present in that form.

953 Preferably, the response factor should be determined in two laboratories using the same protocol. If
 954 different UV-Vis detector types (diode array detector (DAD) and variable wavelength detector
 955 (VWD)) are available, these may also be considered for this measurement.

956 The weighings of impurity and substance to be examined should both be corrected for their
 957 respective purity. If the available amount of impurity does not allow any experimental
 958 determination, values from the certificate of analysis may be used. If enough material is available,
 959 the chromatographic purity and water/solvent content of the impurity and the substance to be
 960 examined should be determined beforehand. A provisional value might be assigned on the basis of
 961 the following formula:

$$962 \quad \text{content}(\%) = [100 - (\text{water} + \text{solvents})] \times \frac{\text{chromatographic purity}(\%)}{100}$$

963 where the chromatographic purity is determined by normalisation or using a dilution of the test
 964 solution or of a solution of the impurity.

965 When only a small amount of the impurity is available, analytical procedures with low sample
 966 amounts may be preferred (e.g. thermogravimetric analysis for water/solvents, coulometry for water
 967 and LC to estimate purity by injecting a concentrated solution of the impurity). Suitable alternative
 968 approaches such as a combination of qNMR and LC data or a comparison of LC-UV and LC-CAD

969 may be employed.

970 **Separation methods.** For pharmacopoeial purposes, the objective of a purity test using a separation
971 method will usually be the control of impurities derived from one or more known manufacturing
972 processes and decomposition routes. However, the experimental conditions, especially the detection
973 system, are chosen specifically so as not to make the test unnecessarily narrow in scope.
974 Chromatographic purity tests may often be the best means of providing a general screening of
975 organic impurities derived from new methods of manufacture or accidental contamination. It may
976 be advantageous to supplement a chromatographic test with other chromatographic or non-
977 chromatographic tests.

978 As mentioned in part II.6.8, a chromatographic system applied to purity testing may, when suitable,
979 be applied also for identification.

980 When a related substances test based on a chromatographic technique is carried out, a representative
981 chromatogram is published with the monograph in *Pharmeuropa*. Although the chromatogram will
982 not ultimately be published in the Ph. Eur., it will be transferred to the EDQM Knowledge Database.

983 When a mixture of impurities with or without the substance to be examined is available as a
984 reference substance (e.g. peak identification CRS, impurity mixture CRS or system suitability
985 CRS), a representative chromatogram, if mentioned in the monograph, will be supplied with the
986 reference substance.

987 Monographs should provide a reliable means of locating the impurities used for the system
988 suitability test (SST) and all specified impurities on the chromatogram. Identification of impurities
989 at or below the limit for unspecified impurities is necessary if a correction factor is to be applied.
990 In such cases, these impurities are listed as specified impurities.

991 Peaks may be located using:

- 992 • a reference standard or a reagent for each impurity;
- 993 • a reference standard containing some or all of the impurities, (e.g. peak identification CRS,
994 system suitability CRS).

995
996 Location by relative retention is not generally considered sufficient for pharmacopoeial purposes,
997 especially for gradient elution. Where a reference standard containing one or several impurities,
998 with or without the substance to be examined, is to be used, a sample of each specified impurity
999 should be provided to the EDQM to enable the establishment of the reference standard.

1000 In general, relative retention is given to one decimal place. However, it is given to two decimal
1001 places where necessary to indicate the elution order of closely eluting peaks. The following general
1002 considerations apply to separation techniques:

- 1003 • high concentrations/loadings are normally used since the symmetry of the principal
1004 peak or shape of the spot is not critical in impurity testing, so long as there is no
1005 interference. When using an external standard in quantitative determinations, the response
1006 of the principal peak in the chromatogram obtained with the test solution does not need to
1007 be in the linear range of the detector;
- 1008 • in general tests for related substances, the substance to be examined should not be
1009 chemically modified (e.g. derivatisation) before purity testing since the impurity pattern
1010 may be modified;

- 1011 • similarly, extraction of the free base or acid prior to impurity testing is to be avoided;
- 1012 • t_R of the principal peak is determined using the diluted test solution (to increase accuracy
- 1013 while avoiding saturation effects).

1014 *II.7.8.1. Thin-layer chromatography (2.2.27) and high-performance thin-layer chromatography*
1015 *for herbal drugs and herbal drug preparations (2.8.25)*

1016 TLC methods should only be used to control a specified impurity and where LC, GC or CE methods
1017 are not appropriate (usually due to a lack of a suitable detection system). More information on
1018 HPTLC can be found in the *Technical guide for the elaboration of monographs on herbal drugs*
1019 *and herbal drug preparations*.

1020 Commercially available pre-coated plates, described in general chapter 4.1.1. *Reagents*, are to be
1021 used; the trade name of the plate found to be suitable during the elaboration of the monograph is
1022 indicated in a footnote to the draft monograph and added to the EDQM Knowledge Database after
1023 the monograph is adopted. In addition to information on the coating material used (type of coating
1024 material, type of binder), general chapter 4.1.1. *Reagents* describes a suitability test procedure
1025 under *TLC silica gel plate R*. The monograph must describe the type of plate, including the particle
1026 size for HPTLC plates, and include a system suitability requirement. It is often the case that the
1027 substances that would be best suited for a SST will not be readily available individually, in which
1028 case a sample of the substance to be examined containing them as contaminants or even a
1029 deliberately spiked sample may then be prescribed. Permissible adjustments to the different
1030 parameters are indicated in general chapter 2.2.46. *Chromatographic separation techniques*.

1031 If any pre-treatment is required or if the chromatography is carried out in unsaturated conditions
1032 for the satisfactory conduct of the test, then this information is included in the text of the
1033 monograph. This especially applies to the use of reverse-phase plates.

1034 One or more dilutions of the substance to be examined will often prove adequate for reference
1035 purposes, provided the impurities to be compared exhibit a similar behaviour under the chosen
1036 chromatographic conditions. This implies that the spots to be compared must be sufficiently close
1037 in terms of their R_F value to minimise errors introduced by different diffusion of the substances
1038 during their migration. Otherwise, reference solutions containing the specified impurities are to be
1039 employed. It may be necessary to instruct the analyst to disregard a spot – often due to the non-
1040 migrating counter-ion of a salt – remaining on the starting line.

1041 Summation of the responses exhibited by each individual spot is only acceptable when appropriate
1042 equipment is prescribed. It is not recommended to set a limit or limits for the concentration of
1043 impurities without a limit on their number, otherwise the total theoretical impurity level would be
1044 unacceptably high. This situation may be counteracted by limiting the impurities on two or more
1045 levels, allowing only a defined number to be at the higher level and the rest below the lower level.
1046 As examples, the test may specify that no contaminant may exceed a relative concentration of 1%
1047 and that only one may exceed 0.25%, or that no contaminant may exceed a relative concentration
1048 of 1%, only one contaminant above 0.5% and no more than four contaminants above 0.25%.

1049 *II.7.8.2. Liquid chromatography (2.2.29)*

1050 Defining the appropriate chromatographic system will often be one of the major problems to be
1051 dealt with when developing a pharmacopoeial purity test based on chromatography. In LC, the
1052 matter is further complicated by the existence of numerous variants of stationary phases, especially

1053 amongst the chemically bonded reverse-phase materials for which not only brand-to-brand but
 1054 occasionally also batch-to-batch variations occur, all of which can influence a given separation.
 1055 Once the type of stationary phase tested has been found to show a satisfactory separation, it must
 1056 be defined by selecting the appropriate reagent entry. Correspondence tables between the trade
 1057 name of the LC columns and the description of the stationary phases are available on the Extranet,
 1058 General Information for Experts section. Particle size (μm) is stated in the analytical procedure; for
 1059 size-exclusion chromatography, particle size (μm) and pore size (nm) are stated. The trade name of
 1060 the column(s) found to be suitable during the elaboration of the monograph is indicated in a
 1061 footnote to the draft monograph and is transferred to the EDQM Knowledge Database after the
 1062 monograph is adopted.

1063 The following are given when describing the chromatographic system: the column dimensions
 1064 (length and internal diameter), nature of the stationary phase (as detailed previously) including any
 1065 steps to prepare or pre-treat it, composition and flow rate of the mobile phase including gradient
 1066 programme (if any), column and autosampler temperature (if differing from room temperature or
 1067 especially if thermostated), method of injection (if important), injection volume and method of
 1068 detection.

1069 If a pre-column is deemed useful during the elaboration of the monograph and the validation data
 1070 has been obtained using the pre-column, its use is normally stated in the monograph.

1071 Depending on the detection wavelength selected, the analyst should choose a suitable grade of
 1072 solvent when preparing the mobile phase. The following guidance applies to the most frequently
 1073 used solvents, methanol and acetonitrile. If water is used as a component of the mobile phase, *water*
 1074 *for chromatography R* should be used.

Wavelength intervals	Acetonitrile grade	Methanol grade
$\lambda \geq 250 \text{ nm}$	<i>Acetonitrile R</i>	<i>Methanol R</i>
$220 \text{ nm} \leq \lambda < 250 \text{ nm}$	<i>Acetonitrile for chromatography R</i>	<i>Methanol R1</i>
$\lambda < 220 \text{ nm}$	<i>Acetonitrile R1</i>	<i>Methanol R2</i>

1075

1076 Permissible adjustments to the different parameters are indicated in general chapter
 1077 2.2.46. *Chromatographic separation techniques*.

1078 Wherever possible, test and reference solutions are prepared using the mobile phase as the solvent
 1079 in order to minimise peak anomalies.

1080 Unlike solutions for quantitative use, the quantities prescribed in reference solutions for qualitative
 1081 use only are described without an extra decimal place.

1082 Since many active substances are synthesised by a number of synthetic routes, the list of potential
 1083 impurities to be limited may be large and the analytical challenge to separate them is great. For the
 1084 sake of robustness and reproducibility, isocratic elution is to be preferred when setting up a
 1085 pharmacopoeial procedure. However, because isocratic liquid chromatographic methods may not
 1086 be sufficiently selective, there is an increasing need to employ gradient methods.

1087 When a gradient system is described, all necessary parameters must be clearly given
 1088 (composition of mobile phases, equilibrium conditions, gradient conditions (linear or step), etc.).
 1089 In general, the return to the initial conditions and re-equilibration are not prescribed in monographs

1090 since this is considered to be instrument specific. Should this information be considered important
1091 (e.g. ion-exchange chromatography), it may be added as a note to the draft monograph and
1092 transferred later to the EDQM Knowledge Database.

1093 For gradient elution in LC, an important parameter to be considered is the volume between the
1094 solvent mixing chamber and the head of the column. This volume is referred to as the dwell volume,
1095 “D” (other terms employed include effective system delay volume, dead volume and delay volume).
1096 The dwell volume is dependent on the configurations of the pumping system including the
1097 dimensions of the capillary tubing, the solvent mixing chamber and the injection loop. Large
1098 differences in dwell volume from one pumping system to another will result in differences in elution
1099 of peaks. The greatest effect of differing dwell volumes on retention times is for those substances
1100 that are not strongly retained. Thus, gradient systems should be designed with an initial isocratic
1101 phase so that analytes do not elute too close to the injection peak, making it possible to correct for
1102 marked differences in dwell volume between different gradient pumping systems. The minimum
1103 time for the initial isocratic step will depend on the dwell volume of the system and will allow
1104 equilibration of the system after sample injection. When the initial validation has been performed
1105 without an initial isocratic step, it may not be necessary to revalidate a procedure to which an
1106 isocratic step has been added if analytes do not elute too close to the injection peak. The dwell volume
1107 of the pumping system employed to develop the procedure should be equal to or less than 1.0 mL. If
1108 the procedure is developed using a system with a dwell volume greater than 1.0 mL, then a suitable
1109 initial isocratic step is essential. Experts’ reports should indicate the dwell volume of the instrument
1110 used for their experimental work. This dwell volume will be stated in a footnote in the draft text and
1111 will be transferred to the EDQM Knowledge Database after the monograph is adopted. A method for
1112 determining the dwell volume is provided in general chapter 2.2.46. *Chromatographic separation*
1113 *techniques*.

1114 II.7.8.2.a. System suitability criteria

1115 One or more system suitability criteria are to be included in the test. Requirements given in general
1116 chapter 2.2.46. *Chromatographic separation techniques* are also applicable.

1117 **Separation capacity.** This criterion is necessary when separation techniques are employed for
1118 assays and tests for related substances. The following approaches, most of which require the
1119 separation or partial separation of a critical pair, are acceptable for a SST for selectivity:

- 1120 • **Resolution.** As calculated by the formula given in general chapter
1121 2.2.46. *Chromatographic separation techniques* using two closely eluting peaks (critical
1122 pair). In cases where several closely eluting impurities are present, it may be useful to
1123 describe more than one resolution requirement, particularly in gradient systems. The
1124 resolution test described should ensure that all the impurities controlled by the procedure
1125 and not just the critical pair are separated from each other and from the principal peak.
1126 Peaks of different heights may be used to calculate the resolution provided the detector is
1127 not saturated.
- 1128 • **Peak-to-valley ratio.** This can be employed when complete separation between two
1129 adjacent peaks cannot be achieved (i.e. when the resolution is less than 1.5). The minimum
1130 requirement for peak-to-valley ratio should not be less than 1.5. Better separation is often
1131 necessary to ensure a meaningful integration of impurity peaks. When the quantitative
1132 composition of a reference standard used in this test changes (replacement batch), it is
1133 necessary to check whether the SST requirements need to be adjusted.

1134

1135 When gradient elution is described, describing a system suitability requirement for each critical
1136 gradient step is desirable.

1137

1138 *In situ* degradation such as oxidation, hydrolysis, *Z-E* isomerisation or ring closure offers an
1139 alternative approach for defining the suitability of the system, provided that the solution of the
1140 substance can be degraded, in mild “stress” conditions within a reasonably short time, to produce
1141 decomposition products. The peaks of these products can then be used to determine a resolution
1142 or a peak-to-valley ratio. This may be a useful alternative to using impurity reference standards.

1143 In exceptional cases, a chromatogram of an impure or preferably “spiked” substance can also be
1144 employed to define the system. In this case, a chromatogram is usually supplied with the reference
1145 substance (for system suitability or for peak identification) or the peak identification is described in
1146 the text of the test for related substances (e.g. when only one impurity is to be identified).

1147 The use of a spiked (or impure) substance requires procurement of sufficient material to establish
1148 the reference substance used and, in the future, replacement of the SST material with material
1149 exhibiting the same characteristics.

1150 It should be noted that retention times or relative retention values are given only for information
1151 and do not constitute alternative system suitability criteria.

1152 **Sensitivity.** The disregard limit/reporting threshold serves a dual purpose:

- 1153 • decision criterion for whether a peak area or a corrected peak area of an impurity is
1154 to be included in the total of impurities;
- 1155 • general criterion for determining compliance of the actual chromatographic system with
1156 the requirement of general chapter 2.2.46. *Chromatographic separation techniques*
1157 (signal-to-noise (S/N) ratio ≥ 10 at the disregard limit/reporting threshold).

1158

1159 Typically, the disregard limit for substances covered by a monograph is set in accordance with the
1160 reporting threshold given in Table 2034.-1 (see *Substances for pharmaceutical use (2034)*).
1161 However, disregard limits are only described when the comparative style is used for the related
1162 substances test; new and revised monographs should be written in the quantitative style and include
1163 a reporting threshold. This threshold helps compensate for differences in sensitivity that can be
1164 observed when different analytical systems are being employed.

1165 When the normalisation procedure is used for quantitation, a reporting threshold is always included
1166 in the test.

1167 When external standardisation is used, if several impurities are limited and a limit for total
1168 impurities is prescribed, a reporting threshold is included in the test. When only one impurity is
1169 limited, no reporting threshold is included, but if the sensitivity is borderline, a minimum S/N
1170 requirement may be added to the monograph.

1171 For specified impurities with CFs > 1.25 (i.e. response factors < 0.8), the peak should be
1172 quantifiable not only at its limit, but also down to the disregard limit/reporting threshold, which is
1173 important for determining of the sum of impurities. Therefore, if the general signal-to-noise
1174 requirement of 10 is not applicable, it may be necessary to add a specific sensitivity criterion (S/N)
1175 for this impurity.

1176 *Example: impurity X is specified at 0.15% with a correction factor of 5 and a general disregard*

1177 *limit/reporting threshold at 0.05%. For the impurity X under consideration, the sensitivity of the*
 1178 *procedure is sufficient if:*

- 1179 • (1) *a S/N ratio of minimum 10 is obtained with a 0.05% (relative to the test solution) solution*
 1180 *of impurity X, when impurity X is available as a reagent/CRS and used as external standard;*
 1181 *or*
- 1182 • (2) *a S/N ratio of minimum 50 (10 x 5 for the correction factor) is obtained with a 0.05%*
 1183 *solution of the active substance when impurity X is not available.*

1184 *Option (2) is preferred when only limited amounts of the isolated impurity are available and the*
 1185 *correction factor of the specified impurity is between 0.2 and 5. Outside this range, it is preferable*
 1186 *to use the impurity as external standard to avoid the additional uncertainty introduced by the*
 1187 *multiplication factor. In the case of option (2), since the correction factor of impurity X is 5 (i.e. the*
 1188 *response factor is 0.2) and a dilution of the test solution is used for the quantitation, it is*
 1189 *recommended to verify the sensitivity of the procedure during its validation. The S/N ratio of the*
 1190 *impurity peak at the reporting threshold should be at least 10 to be quantifiable. To take account of*
 1191 *different sensitivities of equipment used, a minimum S/N ratio should be described in monographs*
 1192 *where the observed S/N of the impurity peak is not higher than 50 at the reporting threshold. The*
 1193 *introduced S/N ratio requirement should be at least 10 times the correction factor (e. g. correction*
 1194 *factor is 4, then S/N requirement should be at least 40).*

1195 *Example 1: Rosuvastatin calcium: Impurity C, correction factor 1.4, limit 0.8%, reporting threshold*
 1196 *0.05%, quantified using a dilution of the test solution of 0.2% (ref. sol. (b)).*

- 1197 → *S/N of impurity C is 55 at the reporting threshold (minimum requirement of 10 to be*
 1198 *quantifiable, but a S/N minimum 50 should be obtained to take account of the sensitivity of*
 1199 *different equipment);*
- 1200 → *S/N of principal peak in ref. sol. (b) is 361, i.e. ≈ 90 at the reporting threshold of 0.05%*
 1201 *(minimum requirement at the reporting threshold: 10×1.4 (CF) = 14).*

1202 *Conclusion:* *the procedure is very sensitive so a minimum S/N is not required in the monograph.*

1204 *Example 2: Correctoprolol (theoretical case): Impurity A, correction factor 2.2, limit 0.2%,*
 1205 *reporting threshold 0.05%, quantified using a dilution of the test solution of 0.1% (ref. sol. (b)).*

- 1206 → *S/N of impurity A is 35 at the reporting threshold (minimum requirement of 10 to be*
 1207 *quantifiable, but a S/N minimum 50 should be obtained to take account of the sensitivity of*
 1208 *different equipment)*
- 1209 → *S/N of principal peak in ref. sol. (b) is 154, i.e. 77 at the reporting threshold of 0.05%*
 1210 *(minimum requirement at the reporting threshold 10×2.2 (CF) = 22).*

1211 *Conclusion:* *based on these results, the sensitivity is sufficient but the minimum requirement might*
 1212 *not be met if less sensitive equipment is used; the recommendation is to include in the monograph*
 1213 *a minimum requirement for S/N of 44 for reference solution (b) (22×2 since ref. sol. (b) at 0.10%).*

1214 For tests for impurities which are limited at ppm level (e.g. DNA-reactive impurities), the SST may
 1215 include a minimum S/N ratio requirement, such as S/N minimum 10 at 50% of the stated limit for
 1216 quantitative tests and S/N minimum 10 at the stated limit for limit tests.

1217 **Repeatability.** In LC with UV detection, it is commonly accepted that the relative standard
 1218 deviation of the peak area obtained on a minimum of three injections of a reference solution
 1219 corresponding to 0.1% of the test solution is not more than 5.0%.

1220 II.7.8.2.b. Quantitation

1221 Quantitation is required for limits applied to specified impurities, unspecified impurities and total
1222 impurities. It is most commonly achieved using an external standard and less commonly by the
1223 normalisation procedure. The use of the normalisation procedure is discouraged because linearity
1224 problems may be observed.

1225 **External standard.** A dilution of the test solution/substance to be examined is used, unless there is
1226 a large difference in the detector response of a specified (or exceptionally an unspecified) impurity
1227 that necessitates the use of a specific external standard, which may be:

- 1228 • a solution of the impurity, normally in the form of a reference standard (preferred option);
- 1229 • a solution of the substance to be examined containing a known amount of the impurity.

1230
1231 Where a dilution of the substance to be examined is used as the external standard, experts
1232 should determine CFs for the impurities, which are indicated in monographs only if they are
1233 outside a range of 0.8-1.25 (i.e. the corresponding response factors are outside a range of 0.8-1.2)
1234 and considered relevant in light of the batch results (see part II.7.8). CFs are normally given to
1235 only one decimal place. The “whole” substance (active moiety, counter-ion and solvate) is taken
1236 into account (e.g. *Donepezil hydrochloride monohydrate (3067)*: “*Calculation of percentage*
1237 *content: for each impurity, use the concentration of donepezil **hydrochloride monohydrate** in*
1238 *reference solution (a)*”).

1239 It is recommended not to apply CFs of less than 0.2 or greater than 5 for specified impurities, but
1240 to use external standards in these cases where possible.

1241 In order to take account of different responses, it is possible to use a wavelength that is different
1242 from the default wavelength for the control of particular impurities. It is understood that the test and
1243 the reference solutions are recorded at the same wavelength unless otherwise prescribed.

1244 The acceptance criteria for related substances tests may be expressed either in terms of comparison
1245 of peak areas (the historically used “comparative test style”) or as numerical values (the
1246 “quantitative test style” that is preferred for new texts or major revisions).

1247 Based on the requirements of the general monograph *Substances for pharmaceutical use*
1248 *(2034)*:

- 1249 • in monographs using the comparative style (acceptance criteria expressed as a
1250 comparison of peak areas), a *disregard limit* is usually set with reference to a dilution of
1251 the test solution;
- 1252 • in monographs referring to numerical values for acceptance criteria, a *reporting threshold*
1253 is defined as a numerical value (%).

1254
1255 **Normalisation procedure.** Quantitation by (area) normalisation requires that all the solutes are
1256 known to be eluted and detected, preferably with uniform response factors, and that the detector
1257 response is linear up to about 120% of the concentrations employed. This must be validated.

1258 As indicated in general chapter 2.2.46. *Chromatographic separation techniques*, peaks due to
1259 solvents or reagents or arising from the mobile phase or the sample matrix, and those at or below
1260 the reporting threshold, are excluded before calculating the percentage content of a substance by
1261 normalisation. An additional reference solution is prescribed to determine the reporting threshold.

1262 The corresponding numerical value (%) is stated in the monograph.

1263 *II.7.8.3. Gas chromatography (2.2.28)*

1264 The difficulties encountered when defining the appropriate chromatographic system in GC purity
1265 tests are similar to those mentioned under LC (part II.7.8.2), although the emphasis may be
1266 elsewhere. The experimental details to be described in a pharmacopoeial test must, therefore,
1267 also be worded as an example so that the chromatographic parameters can be varied to obtain
1268 the required performance. Once the type of stationary phase tested has been found to show a
1269 satisfactory separation, it must be defined by selecting the appropriate reagent entry (4.1.1).
1270 Correspondence tables between the trade name of the GC columns and the reagent stationary phase
1271 description are available on the Extranet, *General Information for Experts* section. The film
1272 thickness (in μm , capillary columns) or the particle size (in μm , packed columns, in older
1273 procedures) is given after the reagent name. The trade name of the column(s) found to be suitable
1274 during elaboration of the monograph is indicated in a footnote to the draft monograph and is
1275 transferred to the EDQM Knowledge Database after the monograph is adopted.

1276 The chromatographic system must be described in essentially the same way as for LC, with the
1277 appropriate adjustments made (temperature programme (if any) instead of elution programme,
1278 injection port and detector temperatures, etc.). The use of packed columns should be avoided.
1279 Permissible adjustments of the different parameters are provided in general chapter 2.2.46.
1280 *Chromatographic separation techniques.*

1281 For reasons of robustness and reproducibility, isothermal operating conditions are preferred.
1282 Quantitation is usually based on an internal standard technique or on the (area) normalisation
1283 procedure. The same limitations concerning summation of peak responses as mentioned for LC
1284 apply here.

1285 For the expression of acceptance criteria, the principles defined in part II.7.8.2.b for LC are to
1286 be applied.

1287 *II.7.8.4. Capillary electrophoresis (CE) (2.2.47)*

1288 CE is increasingly employed to separate and control a large number of impurities of vastly different
1289 polarities. It is also suitable for controlling the content of the unwanted enantiomer in chiral
1290 therapeutic substances. The problem encountered in reverse-phase LC of varying performance from
1291 different stationary phases is avoided if the separation is conducted in a fused-silica capillary.

1292 Joule heating occurs during a run. To obtain satisfactory reproducibility, a defined temperature is
1293 maintained using a thermostat; for instruments without a thermostat, a low voltage should be used.

1294 The limit of detection is adversely affected by the small injection volume and the small detection
1295 pathway in the capillary, even when stacking techniques are applied. For the control of impurities
1296 or assays, it is recommended to use an internal standard to achieve appropriate precision. Otherwise,
1297 the guidance for the use of this technique is similar to that given previously for LC.

1298 For chiral analysis, a chiral reagent is added to the running buffer. The chiral reagent should be
1299 carefully described in the monograph or as a reagent, particularly for cyclodextrin derivatives. Since
1300 many of the cyclodextrin derivatives are randomly substituted, it is important to give the exact or
1301 average degree and location of substitution. More than one batch of the cyclodextrin derivative
1302 should be used for the validation of the analytical procedure.

1303 Experimental parameters to be considered for inclusion in the monograph:

- 1304 • instrumental parameters: voltage, polarity, temperature, capillary size (diameter and
- 1305 length – total and effective – to the detector);
- 1306 • coating material of the capillary (where applicable);
- 1307 • buffer: pH, molarity, composition;
- 1308 • sample solvent;
- 1309 • separation: pole outlet, voltage (U), current (I);
- 1310 • injection: time (t), voltage (U) for electrokinetic injection or pressure difference Δp for
- 1311 hydrodynamic injection;
- 1312 • detection: wavelength, instrumentation;
- 1313 • temperature;
- 1314 • shelf life of solutions;
- 1315 • rinsing procedures (time, reagents, Δp) needed to stabilise the migration times and the
- 1316 resolution of the peaks:
 - 1317 ○ pre-conditioning of a new capillary;
 - 1318 ○ pre-conditioning of the capillary before a series of measurements;
 - 1319 ○ between-run rinsing.

1321 The following information is provided in a footnote and transferred to the EDQM Knowledge
1322 Database after the monograph is adopted:

- 1323 • if a coated capillary is used, the trade name of the capillary found suitable during the
- 1324 elaboration of the monograph;
- 1325 • for chiral separations, the trade name of the chiral reagent (cyclodextrin or other)
- 1326 found to be suitable during the elaboration of the monograph.

1328 In order to minimise the electro-osmotic flow signal, test and reference solutions are, wherever
1329 possible, prepared using *water for chromatography R* or the running buffer as the solvent.

1330 II.7.9. Readily carbonisable substances

1331 The value of this non-specific test has greatly diminished through the introduction of
1332 chromatographic tests providing more information on organic impurities. A test for readily
1333 carbonisable substances is often highly sensitive, which can be a major advantage if this is required.
1334 However, it should be noted that those impurities that produce a coloration under the conditions of
1335 the test will often respond equally well to a test for colour in simple aqueous or alcoholic solution,
1336 and in such cases unnecessary duplication is to be avoided.

1337 If, during the elaboration of a monograph, it appears that impurities may be present that are not
1338 accounted for by other tests, then this test is carried out and, if appropriate, included in the
1339 monograph.

1340 II.7.10. Foreign anions and/or cations

1341 Since strong inorganic acids and bases are widely used in synthesis, the contents of foreign anions
1342 and/or cations in a substance can be indicative of the extent to which it has been purified. They can

1343 also reveal whether contamination with closely related substances has taken place. At the same
1344 time, impurities that are typically ionic can often be removed from poorly water-soluble substances
1345 by treatment with water without necessarily removing the organic impurities. As a result, tests
1346 for anions and cations cannot replace a test for related substances in organic substances but they
1347 may constitute a useful supplement for water-soluble organic substances. For inorganic substances,
1348 which are usually prepared from other inorganics, a much broader range of tests for foreign ions
1349 must be considered.

1350 When considering the introduction of tests for foreign anions in organic substances, a single test,
1351 either for chlorides, sulfates or – less commonly – nitrates, will usually suffice, even if several
1352 could theoretically be present. The test is then to be carried out on the most abundant anion. When
1353 a test for chlorides is considered (up to 0.10%) a limit test should be used instead of titration.

1354 Certain cations must be stringently limited because of their toxicity or catalytic activity. These are
1355 treated separately in part II.7.11. In organic substances, the majority of cations are adequately
1356 controlled via a determination of sulfated ash, unless there are special reasons for limiting their
1357 presence, either individually or in smaller groups (see part II.7.18).

1358 II.7.11. Elemental Impurities

1359 Since the scope of the ICH guideline covers all medicinal products for human use on the market, a
1360 cross-reference to general chapter 5.20 (linked to the ICH Q3D guideline) has been introduced in
1361 general monograph *Pharmaceutical preparations (2619)*, rendering the guideline mandatory.

1362 Since the 9th Edition of the Ph. Eur., all the tests for heavy metals (2.4.8) have been deleted from
1363 individual monographs on substances for both human and veterinary use. As of the 11th Edition,
1364 tests for heavy metals will also be deleted from individual monographs on substances for veterinary
1365 use only. In both cases, no such test will be included in new monographs. For products within the
1366 scope of ICH Q3D, users are expected to apply the guidance laid down in the guideline, and
1367 analytical procedures may be developed with the help of general chapter 2.4.20. *Determination of*
1368 *elemental impurities*.

1369 A different policy is applied for monographs that describe specific tests for elemental impurities. It
1370 is decided on a case-by-case basis if tests are kept for these monographs, particularly for those on
1371 excipients of natural origin.

1372 II.7.12. Loss on drying (2.2.32)

1373 It should be noted that the loss on drying test covers both water and other substances that are volatile
1374 at the prescribed drying temperature.

1375 Generally, only an upper limit for loss on drying is given. If the substance is defined as a hydrate
1376 (or solvate), upper and lower limits are indicated. Drying is carried out to constant mass, unless a
1377 drying time is specified in the monograph. However, it should be noted that any indicated drying
1378 time may not necessarily lead to a dry substance. When a drying time is prescribed, adequate
1379 validation data must be provided. Where the drying temperature is indicated using a single value, a
1380 tolerance of ± 2 °C is understood. For temperatures higher than 105 °C, a greater tolerance has to
1381 be indicated in the monograph.

1382 Based on agreements reached in the Pharmacopoeial Discussion Group (PDG), 105 °C is generally

1383 prescribed for chemicals as the temperature of choice for this test.

1384 General chapter 2.2.32. *Loss on drying* includes four sets of standard conditions that are referred to
1385 in monographs using conventional expressions:

1386 a) “in a desiccator” (over 100 g of *molecular sieve R* at atmospheric or reduced pressure and at
1387 room temperature);

1388 b) “*in vacuo*” (over *molecular sieve R* at a pressure not exceeding 2.5 kPa at room temperature);

1389 c) “*in vacuo* within a specified temperature range” (over *molecular sieve R* at a pressure not
1390 exceeding 2.5 kPa within the temperature range specified in the monograph) [NOTE: the drying
1391 capacity of desiccants decreases when the temperature increases];

1392 d) “in an oven within a specified temperature range” (the preferred specified temperature is 105 °C,
1393 for harmonisation with the Japanese and US pharmacopoeias, with an implied tolerance of
1394 ± 2 °C).

1395 If other conditions are used, in particular lower pressures (e.g. for antibiotics), these are described
1396 in the monograph. A molecular sieve 0.5 nm is the preferred drying agent.

1397 Limits below 10% should be given to two significant figures and limits of 10% or greater to
1398 three significant figures. The sample size is chosen to give a difference of 5-50 mg before/after
1399 drying and is given to four significant figures.

1400 The test can be carried out on a semi-micro scale, in which case the accuracy with which the test
1401 sample is to be weighed should be specified accordingly.

1402 Method d) is to be preferred when the product is sufficiently stable at 105 °C. Otherwise,
1403 method b) or c) is usually applied. It is important to remember, however, that organic solvents are
1404 not always easily removed (e.g. organic solvents in colchicine).

1405 II.7.13. Thermogravimetry (2.2.34)

1406 This method can be used to determine loss on drying when the amount of substance has to be
1407 restricted, to reduce analyst exposure to toxic substances (e.g. vincristine sulfate and vinblastine
1408 sulfate) or if the substance is only available in limited quantities.

1409 II.7.14. Semi-micro determination of water (2.5.12) – volumetric Karl-Fischer

1410 The commercial name of the titrant and the solvent used during elaboration of the monograph
1411 should be indicated in a footnote to the monograph; it will be transferred to the EDQM Knowledge
1412 Database after the monograph is adopted.

1413 Limits below 10% should be given to two significant figures and limits of 10% or greater to
1414 three significant figures. If water content is less than 0.5%, it is recommended to switch to micro
1415 determination of water. The sample size is chosen to obtain a titration volume of about 1 mL and
1416 should be given to three significant figures; it may be necessary to lower the strength of the titrant
1417 when testing samples with low water content.

1418 In the case of well-defined hydrates, water content is specified as a range, whereas a maximum
1419 content is generally prescribed for products containing variable quantities of water. When more than

1420 one form is identified, a cross-reference to the water test is placed in the IDENTIFICATION section of
1421 the monograph.

1422 II.7.15. Micro determination of water (2.5.32) – coulometric Karl-Fischer

1423 No detailed description for the composition of the electrolyte (anolyte and catholyte) reagent is
1424 given in this general chapter since almost all laboratories use commercially available, ready-to-use
1425 reagents.

1426 The commercial name of the titrant (electrolyte reagent) used during elaboration of the monograph
1427 should be indicated in a footnote to the monograph; it will be transferred to the EDQM Knowledge
1428 Database after the monograph is adopted.

1429 The method of sample preparation must be described. If dissolution in a water-free solvent is
1430 necessary, the solvent and the volume must be given. When the oven technique is used to release
1431 the water from the sample, the heating temperature is stated in the monograph. The selected gas and
1432 gas flow rate are indicated in a footnote and transferred to the EDQM Knowledge Database. The
1433 heating time may also be indicated, depending on the instrument used. The direct introduction of
1434 solid material in the reaction vessel should only be prescribed in exceptional cases (e.g. no suitable
1435 solvent found, degradation of the substance upon heating).

1436 Limits should be expressed to two significant figures. In the case of well-defined hydrates, water
1437 content is specified as a range, whereas a maximum content is generally prescribed for products
1438 containing variable quantities of water. When more than one form is identified, a cross-reference to
1439 the water test is placed in the IDENTIFICATION section of the monograph.

1440 The sample size is normally chosen to have a water content of 100 µg to 10 mg. Titrations down
1441 to 10 µg are prescribed only where the water content is very low or the sample size is limited by
1442 the cost of the substance. The calculation is based on the maximum value as stated in the
1443 monograph. The sample size should be stated to three significant figures.

1444 II.7.16. Gas chromatographic determination of water

1445 This method, using a thermal conductivity detector (TCD), may also be used for the determination
1446 of water.

1447 II.7.17. Determination of water by distillation (2.2.13)

1448 This method is used mainly for herbal drugs. It is applicable to a quantity of substance
1449 capable of yielding 2-3 mL of water.

1450 II.7.18. Sulfated ash (2.4.14)

1451 This test is usually intended for the determination of total foreign cations present in organic
1452 substances and in those inorganic substances which themselves are volatilised under the conditions
1453 of the test. Due to the resulting high bias, the test will be of little value as a purity requirement for
1454 the majority of inorganic salts of organic substances.

1455 The limit in a test for sulfated ash is usually set at 0.1%, unless otherwise justified. The

1456 amount of substance prescribed for the test must be such that a residue corresponding to the limit
1457 will not be less than 1 mg (calculated by mass difference) and the prescribed mass of substance
1458 is then given to the appropriate number of significant figures (1.0 g). If the substance tested contains
1459 fluorine, the monograph should describe the use of a platinum crucible.

1460 II.7.19. Residue on evaporation

1461 The amount of a liquid material prescribed for the test is such that a residue corresponding to the
1462 limit will weigh at least 1.0 mg. The appropriate mass or volume of the substance will normally
1463 be in the range of 10-100 g (or mL).

1464 II.7.20. Residual solvents (2.4.24)

1465 Control of residual solvents is covered in general chapter 5.4. *Residual solvents* and in the general
1466 monograph *Substances for pharmaceutical use (2034)*, which apply the ICH Q3C guideline. A
1467 procedure included in general chapter 2.4.24 must be validated if it is quantitatively applied to
1468 control residual solvents in a substance. Suitable validated procedures may be used instead of those
1469 described in general chapter 2.4.24.

1470 A test for a Class 1 solvent is included in the monograph if it is potentially present in an
1471 approved product.

1472 Tests for Class 2 solvents are not included in monographs since the limit may be set using option 2
1473 of general chapter 5.4. *Residual solvents*, whereby all the ingredients in a medicinal product are
1474 taken into account.

1475 A test for a Class 3 solvent is included if it is potentially present in an approved product at a level
1476 higher than 0.5%, otherwise a test for loss on drying is generally prescribed.

1477 Where a quantitative determination of a residual solvent is carried out and a test for loss on drying
1478 is not carried out, the content of residual solvent is taken into account when calculating the assay
1479 content of the substance, the specific optical rotation and the specific absorbance.

1480 II.7.21. Bacterial endotoxins

1481 When a substance for pharmaceutical use is intended for injection or irrigation, the substance has
1482 to comply with the test for bacterial endotoxins. Guidance on how to establish limits is given in
1483 general text 5.1.10. *Guidelines for using the test for bacterial endotoxins*. In principle, the test is no
1484 longer added to new monographs. Compliance with the test is requested via the general monograph
1485 *Substances for pharmaceutical use (2034)*. A test is included only where a specific procedure has
1486 to be described (e.g. if a specific sample preparation has to be used or if a specific method of general
1487 chapter 2.6.14 has to be applied). If a test is included in the monograph, no limit is given.

1488 For monographs under revision, the decision whether or not to delete the test and/or the limit is
1489 made on a case-by-case basis.

1490 During the elaboration and, if applicable, revision of a monograph, data are gathered and examined
1491 in order to decide whether there is a need to give a specific sample preparation procedure in the
1492 individual monograph or whether it can be considered that the topic of bacterial endotoxins is
1493 adequately covered by the general monograph *Substances for pharmaceutical use (2034)*. These

1494 data include but are not limited to: validation of the bacterial endotoxin test, batch data and
1495 demonstration of absence of interference of the substance with the test.

1496 If a test for pyrogens is replaced by a test for bacterial endotoxins, the decision concerning whether
1497 to include a test in the monograph follows the considerations described above. The information on
1498 the replacement of the testing procedures is given in the EDQM Knowledge Database.

1499

1500 II.8 ASSAY

1501 Assays are included in monographs unless:

- 1502 • all the foreseeable impurities can be detected and limited with sufficient accuracy and
1503 precision;
- 1504 • certain quantitative tests, similar to assays, are carried out with sufficient accuracy
1505 and precision (specific optical rotation, specific absorbance, etc.);
- 1506 • specific profiles of relevant substances such as composition of the fatty acid fraction
1507 (see general chapter 2.4.22. *Composition of fatty acids by gas chromatography*) or
1508 composition of the sterol fraction of a fat or fatty oil (see general chapter 2.4.23. *Sterols
1509 in fatty oils*) have been established;
- 1510 • the tests performed are sufficient to establish the quality of the substance (typically for
1511 non-active substances, e.g. ethanol or water).

1512

1513 More than one assay may be necessary if:

- 1514 • the substance to be examined consists of a combination of two parts that are not necessarily
1515 present in absolutely fixed proportions, so that the assay of only one of the two
1516 constituents does not make it possible to determine the substance as a whole correctly
1517 (e.g. theophylline and ethylenediamine);
- 1518 • the results of the quantitative tests do not fully represent the therapeutic activity, in
1519 which case a biological assay is included.

1520

1521 In the case of well-defined salts, the assay of only one of the ions, preferably the pharmacologically
1522 active moiety, is generally considered sufficient. It is only rarely necessary to determine all the ions
1523 and, in any case, it is considered superfluous to determine one of these by two methods even when
1524 these rely on different analytical principles.

1525 When the identification and purity tests are sufficiently specific and selective, a non-specific but
1526 precise assay may be used (e. g. by volumetric titration), rather than a specific and less precise assay.
1527 When an active substance is covered by a monograph and a monograph on the corresponding
1528 medicinal product already exists or is being elaborated, the same chromatographic assay procedure
1529 should ideally be described.

1530 Every assay procedure proposed must be validated according to the procedures described for the
1531 different techniques in part III.

1532 II.8.1. Absorption spectrophotometry (ultraviolet and visible) (2.2.25)

1533 UV-Vis spectrophotometric assays may be carried out directly or after a suitable chemical
1534 reaction. Other techniques are usually preferred. When monographs containing an assay based
1535 solely on UV-Vis spectrophotometry are revised, it is recommended to replace it with a
1536 chromatographic-separation-based assay or a titration.

1537 II.8.1.1. Direct measurement

1538 This is not specific but may be of acceptable accuracy and precision and is usually performed
1539 without a reference substance: the absorbance of the solution is measured at the specified absorption
1540 maximum, and the content of the substance to be examined is calculated on the basis of the specific
1541 absorbance stated in the monograph.

1542 The specific absorbance value must be verified for a new substance. The manufacturer must
1543 supply validation data supporting the acceptance of the “true” value, otherwise this value needs
1544 to be validated by the (co-)rapporteur. These validation data include, for example, the purity of the
1545 substance used to determine the value, which is demonstrated by employing several methods
1546 (separation techniques, absolute methods, the response factors of likely impurities, solvents, etc.).

1547 With a reference substance, the active substance content is calculated by comparing the absorbance
1548 of the solution to be examined with that of a solution of the reference substance.

1549 For experimental details and results, see general chapter 2.2.25. *Ultraviolet and visible absorption*
1550 *spectrophotometry*.

1551 II.8.1.2. Measurement after a colour reaction

1552 This measurement is carried out by comparison with a reference substance. The results may be
1553 less accurate and precise due to the sample treatment.

1554 II.8.2. Volumetric analysis

1555 The amount of the substance taken for the assay is such that the final titration, using automatic
1556 titration equipment, will consume less than 10 mL – preferably 7-8 mL – of titrant in order to
1557 permit the use of standard titration equipment. In the case of back-titration, the fixed volume of the
1558 first titrant added must also be adequate so that the result of the assay will not be based upon
1559 volumes that are too similar.

1560 Blank tests are to be prescribed whenever necessary, unless already stipulated in the corresponding
1561 general chapter. A blank test can be avoided when the composition of the medium in which a
1562 volumetric solution is standardised is the same as that in which it is to be used.

1563 Either potentiometric end-point detection or a visual colour change indicator can be specified in the
1564 monograph, when an acid-base or redox titration is described. The potentiometric mode of end-
1565 point detection (2.2.20. *Potentiometric titration*) is clearly applicable in almost all cases.
1566 Determination by visual colour change should be avoided, except for complexometric
1567 titrations, where this is generally not possible. Where potentiometric detection is specified, the
1568 appropriate indicator electrode for that purpose is to be given in the text only if necessary (special
1569 type of electrode). The number of inflexion points to be evaluated is given. Other modes of detection
1570 may be specified, such as the amperometric method (2.2.19. *Amperometric titration*) or the

1571 voltametric method (2.2.65. *Voltametric titration*). Whichever mode is used, it must be known to
1572 be appropriately reproducible and preferably stoichiometrically exact. When a visual indicator is
1573 specified, the colour change is given only when it is different from that described in general chapter
1574 4.1.1. *Reagents*.

1575 The following methods are recommended for the titration of halide salts of organic bases and some
1576 quaternary ammonium substances:

1577 a) Alkalimetric titration in an alcoholic medium. This is the preferred option for the volumetric
1578 titration of halide salts. When carrying out alkalimetric titration, it may be necessary to add 5 mL
1579 of 0.01 M hydrochloric acid before the titration and to measure the volume of titrant required
1580 between the two points of inflexion. However, it is advisable to test the feasibility of the titration
1581 before adding 0.01 M hydrochloric acid.

1582 b) Titration with perchloric acid, the sample being dissolved in anhydrous acetic acid before adding
1583 acetic anhydride or a mixture of acetic anhydride and anhydrous formic acid.

1584 c) Argentimetry.

1585 d) Methods a) (with the addition of 5 mL of 0.01 M hydrochloric acid) and b) are often suitable for
1586 quaternary ammonium substances.

1587 II.8.3. Chromatography-based techniques

1588 In pharmacopoeial practice, the chromatographic techniques on which assays may be based are
1589 normally limited to LC and GC. The recommendations contained in part II.7.8 on related substances
1590 for LC and GC will also be valid for developing assays based on these techniques. The use of an
1591 external standard in LC and the addition of an internal standard in GC are recommended. Such
1592 methods require the use of a CRS with an assigned content (see part I.7. Reference Standards).

1593 II.8.4. Determination of nitrogen by sulfuric acid digestion (2.5.9)

1594 Any substance to be assayed by this method has a digestion time assigned after determination of
1595 its digestion profile.

1596 The digestion profile may be determined as follows. Several individually weighed portions of the
1597 prescribed amount of substance are assayed in accordance with the general chapter while varying
1598 the time for which the reaction mixture is boiled, normally up to 120 min, after the mixture
1599 has cleared. By plotting the resulting nitrogen content against the boiling time, it is possible to
1600 determine the minimum digestion time necessary to obtain constant values. In cases where the
1601 necessary digestion time exceeds 30 min, the time required is indicated in the monograph.

1602 II.9 STORAGE

1603 Although the statements given under this heading in a monograph of the Ph. Eur. do not constitute
1604 pharmacopoeial requirements, the appropriate information to safeguard the quality of a
1605 pharmacopoeial material during storage is to be given here where appropriate.

1606 The terminology given in the *General Notices* and in general chapter 3.2. *Containers* should be
1607 used. Protection against loss or uptake of constituents via the gas phase requires an “airtight

1608 container". A "sealed container" is also "tamper-evident", while the converse is not necessarily true.
1609 Manufacturers should be requested to provide stability data. In considering the guidance to be given
1610 in the monograph, the behaviour of the material towards exposure to atmospheric air, various
1611 degrees of humidity, different temperatures and actinic light are to be taken into account. Where a
1612 substance is described in the CHARACTERS section as hygroscopic, deliquescent or sensitive to air,
1613 "airtight container" is indicated. When a substance is known to be sensitive to actinic light,
1614 "protected from light" is indicated.
1615 In this context, it must be borne in mind that the method given in general chapter 5.11. *Characters*
1616 *section in monographs* for hygroscopicity is not to be used to define storage conditions. This is a
1617 rapid method that gives an indication of the hygroscopicity of the substance as an aid to the analyst
1618 so that the proper handling precautions can be taken when examining the substance in laboratory
1619 conditions.

1620 II.10 LABELLING

1621 Since the labelling of medicine is subject to international agreements and supranational and national
1622 regulations, the indications given under LABELLING are not exhaustive: they consist of both
1623 mandatory statements (necessary for the application of the monograph) and other statements that
1624 are included only as recommendations. In general, for bulk active substances, the requirements
1625 given in this section of a pharmacopoeial monograph are confined to those essential for the correct
1626 interpretation of the other requirements in the monograph. When, for example, a starting material
1627 has to comply with additional requirements (e.g. sterility), the label must state, where appropriate,
1628 that the contents of the container are suitable for that use. Furthermore, when the inclusion of certain
1629 stabilisers or other additives is authorised by the monograph, their presence will generally have
1630 to be declared on the label.

1631 II.11 IMPURITIES

1632 Monographs on organic chemicals should have an IMPURITIES section defining the impurities that
1633 are known to be detected by the prescribed tests and that have been considered in defining
1634 the acceptance criteria for related substances. Subheadings are given for "Specified impurities" and
1635 "Other detectable impurities". All specified impurities covered by the monograph are included in
1636 this section. In addition, it may be useful to include information on other detectable impurities,
1637 (impurities whose detection by the monograph tests is known and has been experimentally verified)
1638 but that are not known to occur in current production batches above the identification threshold).

1639 The IMPURITIES section gives a list showing the chemical structure and chemical nomenclature (of
1640 the base/acid/neutral substance, not as the salt) for each impurity. Impurities are designated by a
1641 capital letter (A, B, C, D, etc.). Trivial names may be included in parenthesis in cases where they
1642 are considered to be informative.

1643 The IMPURITIES section may also give information on the tests that limit a given impurity, for
1644 example where this test is not a "Related substances" test (e.g. enantiomeric purity) or where there
1645 is more than one "Related substances" test.

1646 **II.12 FUNCTIONALITY-RELATED CHARACTERISTICS**

1647 Monographs on excipients may have a section on FUNCTIONALITY-RELATED CHARACTERISTICS
1648 (FRCs). This is introduced by a standard paragraph indicating the non-mandatory status. The uses
1649 for which each FRC is relevant are also stated. FRCs may be presented by:

- 1650 • giving simply the name;
- 1651 • giving the name and a recommended method from the general chapters of the Ph. Eur.;
- 1652 • giving the name, a recommended method and typical values;
- 1653 • giving the name and a cross-reference to a test present in the mandatory part of the
1654 monograph.
- 1655

1656 III. ANALYTICAL VALIDATION

1657 This section describes the procedures to be carried out to validate the tests that are intended to be
1658 described in a Ph. Eur. monograph. These tests include tests for identification, instrumental and
1659 non-instrumental tests for the control of impurities, and the assay procedure. The validation
1660 requirements vary according to the type of test and the technique employed. This section contains
1661 the texts on Analytical Validation adopted by the ICH in 1994, the Extension of the ICH text
1662 “Validation of Analytical Procedures” which includes valuable information concerning validation
1663 requirements for registration applications and specific guidelines for the validation of
1664 pharmaceutical procedures using different analytical techniques.

1665 III.1 DEFINITIONS AND TERMINOLOGY

1666 [ICH document. Text adopted and published by the *International Conference on Harmonisation*
1667 *of Technical Requirements for the Registration of Pharmaceuticals for Human Use* (1994)].

1668 III.1.1. Introduction

1669 This document presents a discussion of the characteristics for consideration during the validation
1670 of the analytical procedures included as part of registration applications submitted within the EC,
1671 Japan and USA. This document does not necessarily seek to cover the testing that may be required
1672 for registration in, or export to, other areas of the world. Furthermore, this text presentation serves
1673 as a collection of terms and their definitions, and is not intended to provide direction on how to
1674 accomplish validation. These terms and definitions are meant to bridge the differences that often
1675 exist between various compendia and regulators of the EC, Japan and USA.

1676 The objective of validation of an analytical procedure is to demonstrate that it is suitable for its
1677 intended purpose. A tabular summation of the characteristics applicable to identification, control of
1678 impurities and assay procedures is included. Other analytical procedures may be considered in
1679 future additions to this document.

1680 III.1.2. Types of analytical procedures to be validated

1681 The discussion of the validation of analytical procedures is directed to the four most common
1682 types of analytical procedures:

- 1683 • Identification tests;
- 1684 • Quantitative tests for impurities' content;
- 1685 • Limit tests for the control of impurities;
- 1686 • Quantitative tests of the active moiety in samples of drug substance or drug product or
1687 other selected component(s) in the drug product.

1688
1689 Although there are many other analytical procedures, such as dissolution testing for drug products
1690 or particle size determination for drug substance, these have not been addressed in the initial text
1691 on validation of analytical procedures. Validation of these additional analytical procedures is
1692 equally important to those listed herein and may be addressed in subsequent documents.

1693 A brief description of the types of tests considered in this document is provided below:

- 1694 • identification tests are intended to ensure the identity of an analyte in a sample. This is
1695 normally achieved by comparison of a property of the sample (e.g. spectrum,
1696 chromatographic behaviour, chemical reactivity, etc.) to that of a reference standard;
- 1697 • testing for impurities can be either a quantitative test or a limit test for the impurity in a
1698 sample. Either test is intended to accurately reflect the purity characteristics of the sample.
1699 Different validation characteristics are required for a quantitative test than for a limit test;
- 1700 • assay procedures are intended to measure the analyte present in a given sample. In the
1701 context of this document, the assay represents a quantitative measurement of the major
1702 component(s) in the drug substance. For the drug product, similar validation
1703 characteristics also apply when assaying for the active or other selected component(s).
1704 The same validation characteristics may also apply to assays associated with other
1705 analytical procedures (e.g. dissolution).
1706

1707 III.1.3. Validation characteristics and requirements

1708 The objective of the analytical procedure should be clearly understood since this will govern the
1709 validation characteristics which need to be evaluated. Typical validation characteristics that
1710 should be considered are listed below:

- 1711 • Accuracy;
- 1712 • Precision;
 - 1713 ○ Repeatability;
 - 1714 ○ Intermediate precision;
- 1715 • Specificity;
- 1716 • Detection limit;
- 1717 • Quantitation limit;
- 1718 • Linearity;
- 1719 • Range.

1720

1721 Each of these validation characteristics is defined in the attached Glossary. The table lists those
1722 validation characteristics regarded as the most important for the validation of different types of
1723 analytical procedures. This list should be considered typical for the analytical procedures cited but
1724 occasional exceptions should be dealt with on a case-by-case basis. It should be noted that
1725 robustness is not listed in the table but should be considered at an appropriate stage in the
1726 development of the analytical procedure.

1727 Furthermore revalidation may be necessary in the following circumstances:

- 1728 • changes in the synthesis of the drug substance;
- 1729 • changes in the composition of the drug product;
- 1730 • changes in the analytical procedure.

1731

1732 The degree of revalidation required depends on the nature of the changes. Certain other
1733 changes may require validation as well.

1734

CHARACTERISTIC	TYPE OF ANALYTICAL PROCEDURE			
	IDENTIFICATION	TESTING FOR IMPURITIES		ASSAY
		Quantitative test	Limit test	Dissolution Measurement only Content / potency
Accuracy	–	+	–	+
Precision				
Repeatability		+	–	+
Intermediary Precision		+*	–	+*
Specificity**	+	+	+	+
Detection Limit	–	-***	+	–
Quantitation Limit	–	+	–	–
Linearity	–	+	–	+
Range	–	+	–	+

1735

– signifies that this characteristic is not normally evaluated.

1736

+ signifies that this characteristic is normally evaluated.

1737

* in cases where reproducibility (see Glossary) has been performed, intermediate precision is not needed.

1738

** lack of specificity of one analytical procedure, could be compensated by other supporting analytical procedure(s).

1739

*** may be needed in some cases.

1740

1741

III.1.4. Glossary

1742

Analytical procedure. The analytical procedure refers to the way of performing the analysis. It should describe in detail the steps necessary to perform each analytical test. This may include but is not limited to: the sample, the reference standard and the preparation of reagents, use of the apparatus, generation of the calibration curve, use of the formulae for the calculation, etc.

1743

1744

1745

1746

Specificity. Specificity is the ability to assess unequivocally the analyte in the presence of components which may be expected to be present. Typically these might include impurities, degradation products, matrix, etc.

1747

1748

1749

Lack of specificity of an individual analytical procedure may be compensated by other supporting analytical procedure(s).

1750

1751

This definition has the following implications:

1752

- Identification: to ensure the identity of an analyte.

1753

- Purity tests: to ensure that all the analytical procedures performed allow an accurate statement of the content of impurities of an analyte, i.e. related substances test, heavy metals, residual solvents content, etc.

1754

1755

1756

- Assay (content or potency): to provide an exact result which allows an accurate statement on the content or potency of the analyte in a sample.

1757

1758

1759

Accuracy. The accuracy of an analytical procedure expresses the closeness of agreement between the value which is accepted either as a conventional true value or an accepted reference value and

1760

1761 the value found. This is sometimes termed trueness.

1762 **Precision.** The precision of an analytical procedure expresses the closeness of agreement (degree
1763 of scatter) between a series of measurements obtained from multiple sampling of the same
1764 homogeneous sample under the prescribed conditions. Precision may be considered at three levels:
1765 repeatability, intermediate precision and reproducibility.

1766 Precision should be investigated using homogeneous, authentic samples. However, if it is not
1767 possible to obtain a homogeneous sample, it may be investigated using artificially prepared samples
1768 or a sample solution.

1769 The precision of analytical procedure is usually expressed as the variance, standard deviation or
1770 coefficient of variation of a series of measurements.

1771 **Repeatability** expresses the precision under the same operating conditions over a short interval
1772 of time. Repeatability is also termed intra-assay precision.

1773 **Intermediate precision** expresses variations within laboratories: different days, different analysts,
1774 different equipment, etc.

1775 **Reproducibility** expresses the precision between laboratories (collaborative studies, usually
1776 applied to standardisation of methodology).

1777 **Detection limits.** The detection limit of an individual analytical procedure is the lowest amount of
1778 analyte in a sample which can be detected but not necessarily quantitated as an exact value.

1779 **Quantitation limits.** The quantitation limit of an individual analytical procedure is the lowest
1780 amount of analyte in a sample which can be quantitatively determined with suitable precision and
1781 accuracy. The quantitation limit is a parameter of quantitative assays for low levels of substances
1782 in sample matrices, and is used particularly for the determination of impurities and/or degradation
1783 products.

1784 **Linearity.** The linearity of an analytical procedure is its ability (within a given range) to
1785 obtain test results which are directly proportional to the concentration (amount) of analyte in the
1786 sample.

1787 **Range.** The range of an analytical procedure is the interval between the upper and lower
1788 concentration (amounts) of analyte in the sample (including these concentrations) for which it has
1789 been demonstrated that the analytical procedure has a suitable level of precision, accuracy and
1790 linearity.

1791 **Robustness.** The robustness of an analytical procedure is a measure of its capacity to remain
1792 unaffected by small but deliberate variations in method parameters and provides an indication of
1793 its reliability during normal usage.

1794 III.2 METHODOLOGY

1795 [ICH document. Text adopted and published by the *International Conference on Harmonisation of*
1796 *Technical Requirements for the Registration of Pharmaceuticals for Human Use* (1996)].

1797 III.2.1. Introduction

1798 This document is complementary to the parent document which presents a discussion of the
1799 characteristics that should be considered during the validation of analytical procedures. Its purpose
1800 is to provide some guidance and recommendations on how to consider the various validation
1801 characteristics for each analytical procedure. In some cases (for example, demonstration of
1802 specificity) the overall capabilities of a number of analytical procedures in combination may be
1803 investigated in order to ensure the quality of the drug substance or drug product. In addition, the
1804 document provides an indication of the data which should be presented in a new drug application.

1805 All relevant data collected during validation and formulae used for calculating validation
1806 characteristics should be submitted and discussed as appropriate.

1807 Approaches other than those set forth in this guideline may be applicable and acceptable. It is the
1808 responsibility of the applicant to choose the validation procedure and protocol most suitable for
1809 their product. However, it is important to remember that the main objective of validation of an
1810 analytical procedure is to demonstrate that the procedure is suitable for its intended purpose. Due
1811 to their complex nature, analytical procedures for biological and biotechnological products in some
1812 cases may be approached differently than in this document.

1813 Well-characterised reference materials, with documented purity, should be used throughout the
1814 validation study. The degree of purity required depends on the intended use.

1815 In accordance with the parent document and for the sake of clarity, this document considers the
1816 various validation characteristics in distinct parts. The arrangement of these parts reflects the
1817 process by which an analytical procedure may be developed and evaluated.

1818 In practice, it is usually possible to design the experimental work such that the appropriate
1819 validation characteristics can be considered simultaneously to provide a sound, overall knowledge
1820 of the capabilities of the analytical procedure, for instance: specificity, linearity, range, accuracy
1821 and precision.

1822 III.2.2. Specificity

1823 An investigation of specificity should be conducted during the validation of identification tests,
1824 the determination of impurities and the assay. The procedures used to demonstrate specificity will
1825 depend on the intended objective of the analytical procedure.

1826 It is not always possible to demonstrate that an analytical procedure is specific for a particular
1827 analyte (complete discrimination). In this case a combination of two or more analytical procedures
1828 is recommended to achieve the necessary level of discrimination.

1829 *III.2.2.1. Identification*

1830 Suitable identification tests should be able to discriminate between substances of closely related
1831 structures which are likely to be present. The discrimination of a procedure may be confirmed
1832 by obtaining positive results (perhaps by comparison with a known reference material) from
1833 samples containing the analyte, coupled with negative results from samples which do not contain
1834 the analyte. In addition, the identification test may be applied to materials structurally similar to or
1835 closely related to the analyte to confirm that a positive response is not obtained. The choice of such

1836 potentially interfering materials should be based on sensible scientific judgement with a
1837 consideration of the interferences which could occur.

1838 *III.2.2.2. Assays and impurity tests*

1839 For chromatographic procedures, representative chromatograms should be used to demonstrate
1840 specificity and individual components should be appropriately labelled. Similar considerations
1841 should be given to other separation techniques.

1842 Critical separations in chromatography should be investigated at an appropriate level. For critical
1843 separations specificity can be demonstrated by the resolution of the two components which elute
1844 closest to each other.

1845 In cases where a non-specific assay is used, other supporting analytical procedures should be used
1846 to demonstrate overall specificity. For example, where a titration is adopted to assay the drug
1847 substance, the combination of the assay and a suitable test for impurities can be used.

1848 The approach is similar for both assays and impurity tests:

1849 **Impurities are available**

- 1850 • for the assay, this should involve demonstration of the discrimination of the analyte in the
1851 presence of impurities and/or excipients; practically, this can be done by spiking pure
1852 substances (drug substance or drug product) with appropriate levels of impurities and/or
1853 excipients and demonstrating that the assay result is unaffected by the presence of these
1854 materials (by comparison with the assay result obtained on unspiked samples);
- 1855 • for the impurity test, the discrimination may be established by spiking the drug substance
1856 or drug product with appropriate levels of impurities and demonstrating the separation of
1857 these impurities individually and/or from other components in the sample matrix.
1858 Alternatively, for less discriminating procedures it may be acceptable to demonstrate that
1859 these impurities can still be determined with appropriate accuracy and precision.

1860

1861 **Impurities are not available**

1862 If impurity or degradation product standards are unavailable, specificity may be demonstrated by
1863 comparing the test results of samples containing impurities or degradation products to a second
1864 well-characterised procedure, e.g. pharmacopoeial procedure or other validated analytical procedure
1865 (independent procedure). As appropriate, this should include samples stored under relevant stress
1866 conditions: light, heat, humidity, acid/base hydrolysis and oxidation.

- 1867 • For the assay, the two results should be compared.
- 1868 • For the impurity tests, the impurity profiles should be compared.

1869

1870 Peak purity tests (e.g. diode array, mass spectrometry) may be useful to show that the analyte
1871 chromatographic peak is not attributable to more than one component.

1872 **III.2.3. Linearity**

1873 Linearity should be established across the range (see part III.2.4) of the analytical procedure. It
1874 may be demonstrated directly on the drug substance (by dilution of a standard stock solution) and/or
1875 separate weighings of synthetic mixtures of the drug product components using the proposed

1876 procedure. The latter aspect can be studied during investigation of the range.

1877 Linearity should be established by visual evaluation of a plot of signals as a function of
1878 analyte concentration or content. If there is a linear relationship, test results should be evaluated by
1879 appropriate statistical methods, for example, by calculation of a regression line by the method of
1880 least squares. In some cases, to obtain linearity between assays and sample concentrations, the test
1881 data may have to be subjected to a mathematical transformation prior to the regression analysis.
1882 Data from the regression line itself may be helpful to provide mathematical estimates of the degree
1883 of linearity. The correlation coefficient, y-intercept, slope of the regression line and residual
1884 sum of squares should be submitted. A plot of the data should be included. In addition, an analysis
1885 of the deviation of the actual data points from the regression line may also be helpful for evaluating
1886 linearity.

1887 Some analytical procedures, such as immunoassays, do not demonstrate linearity after any
1888 transformation. In this case the analytical response should be described by an appropriate function
1889 of the concentration (amount) of an analyte in a sample.

1890 For the establishment of linearity, a minimum of five concentrations is recommended. Other
1891 approaches should be justified.

1892 III.2.4. Range

1893 The specified range is normally derived from linearity studies and depends on the intended
1894 application of the procedure. It is established by confirming that the analytical procedure provides
1895 an acceptable degree of linearity, accuracy and precision when applied to samples containing
1896 amounts of analyte within or at the extremes of the specified range of the analytical procedure.

1897 The following minimum specified ranges should be considered:

- 1898 • for the assay of a drug substance or a drug product: from 80 to 120% of the test
1899 concentration;
 - 1900 • for the determination of an impurity: from the quantitation limit (QL) or from 50% of
1901 the specification of each impurity, whichever is greater, to 120% of the specification;
 - 1902 • for impurities known to be unusually potent or to produce toxic or unexpected
1903 pharmacological effects, the detection/quantitation limit should be commensurate with the
1904 level at which the impurities must be controlled. *Note: for validation of impurity test*
1905 *procedures carried out during development, it may be necessary to consider the range*
1906 *around a suggested (probable) limit;*
 - 1907 • if assay and purity are performed together as one test and only a 100% standard is
1908 used, linearity should cover the range from QL or from 50% of the specification of each
1909 impurity, whichever is greater, to 120% of the assay specification;
 - 1910 • for content uniformity, covering a minimum of 70 to 130% of the test concentration,
1911 unless a wider more appropriate range, based on the nature of the dosage form (e.g.
1912 metered dose inhalers) is justified;
 - 1913 • for dissolution testing: $\pm 20\%$ over the specified range, e.g. if the specifications for a
1914 controlled released product cover a region from 20%, after 1 hour, up to 90%, after
1915 24 hours, the validated range would be 0-110% of the label claim.
- 1916

1917 III.2.5. Accuracy

1918 Accuracy should be established across the specified range of the analytical procedure.

1919 *III.2.5.1. Assay*

1920 **Drug substance (Active pharmaceutical ingredient).** Several methods of determining accuracy
1921 are available:

- 1922 • application of an analytical procedure to an analyte of known purity (e.g. reference
1923 material);
- 1924 • comparison of the results of the proposed analytical procedure with those of a second
1925 well-characterised procedure, the accuracy of which is stated and/or defined (independent
1926 procedure);
- 1927 • accuracy may be concurrently determined when precision, linearity and specificity
1928 data are acquired.

1929
1930 **Drug product.** Several methods for determining accuracy are available:

- 1931 • application of the analytical procedure to synthetic mixtures of the drug product
1932 components to which known quantities of the drug substance to be analysed have been
1933 added;
- 1934 • in cases where it is impossible to obtain samples of all drug product components, it
1935 may be acceptable either to add known quantities of the analyte to the drug product or to
1936 compare the results obtained from the second, well-characterised procedure, the
1937 accuracy of which is stated and/or defined (independent procedure);
- 1938 • accuracy may be concurrently determined when precision, linearity and specificity
1939 data are acquired.

1940

1941 *III.2.5.2. Impurities (quantitation)*

1942 Accuracy should be assessed on samples (drug substance/drug product) spiked with known
1943 amounts of impurities.

1944 In cases where it is impossible to obtain samples of certain impurities and/or degradation products,
1945 it is acceptable to compare results obtained by an independent procedure. The response factor of
1946 the drug substance can be used.

1947 *III.2.5.3. Recommended data*

1948 Accuracy should be assessed using a minimum of nine determinations over a minimum of
1949 three concentration levels covering the specified range (e.g. three concentrations/three replicates
1950 each).

1951 Accuracy should be reported as percent recovery by the assay of a known added amount of analyte
1952 in the sample or as the difference between the mean and the accepted true value together with the
1953 confidence intervals.

1954 III.2.6. Precision

1955 Validation of tests for assay and for quantitative determination of impurities includes an
1956 investigation of precision.

1957 *III.2.6.1. Repeatability*

1958 Repeatability should be assessed using:

- 1959 • a minimum of nine determinations covering the specified range for the procedure (e.g.
1960 three concentrations/three replicates each), *or*
1961 • a minimum of six determinations at 100% of the test concentration.
1962

1963 *III.2.6.2. Intermediate precision*

1964 The extent to which intermediate precision should be established depends on the circumstances
1965 under which the procedure is intended to be used. The applicant should establish the effects of
1966 random events on the precision of the analytical procedure. Typical variations to be studied
1967 include days, analysts, equipment, etc. It is not necessary to study these effects individually. The
1968 use of an experimental design (matrix) is encouraged.

1969 *III.2.6.3. Reproducibility*

1970 Reproducibility is assessed by means of an inter-laboratory trial. Reproducibility should be
1971 considered in case of the standardisation of an analytical procedure, for instance, for inclusion of
1972 procedures in pharmacopoeias. These data are not part of the marketing authorisation dossier.

1973 *III.2.6.4. Recommended data*

1974 The standard deviation, relative standard deviation (coefficient of variation) and confidence
1975 interval should be reported for each type of precision investigated.

1976 III.2.7. Detection limit

1977 Several approaches for determining the detection limit are possible, depending on whether the
1978 procedure is a non-instrumental or instrumental. Approaches other than those listed below may
1979 be acceptable.

1980 *III.2.7.1. Based on visual evaluation*

1981 Visual evaluation may be used for non-instrumental methods but may also be used with
1982 instrumental methods.

1983 The detection limit is determined by the analysis of samples with known concentrations of
1984 analyte and by establishing the minimum level at which the analyte can be reliably detected.

1985 *III.2.7.2. Based on signal-to-noise ratio*

1986 This approach can only be applied to analytical procedures which exhibit baseline noise.
1987 Determination of the signal-to-noise ratio is performed by comparing measured signals from

1988 samples with known low concentrations of analyte with those of blank samples and establishing the
 1989 minimum concentration at which the analyte can be reliably detected. A signal-to-noise ratio
 1990 between 3 or 2:1 is generally acceptable.

1991 *III.2.7.3. Based on the standard deviation of the response and the slope*

1992 The detection limit (DL) may be expressed as:

1993
$$DL = \frac{3.3\sigma}{S}$$

1994 σ = the standard deviation of the response,

1995 S = the slope of the calibration curve.

1996 The slope S may be estimated from the calibration curve of the analyte. The estimate of σ may
 1997 be carried out in a variety of ways, for example:

- 1998 • Based on the standard deviation of the blank. Measurement of the magnitude of analytical
 1999 background response is performed by analysing an appropriate number of blank samples
 2000 and calculating the standard deviation of these responses.
- 2001 • Based on the calibration curve. A specific calibration curve should be studied using
 2002 samples containing an analyte in the range of DL. The residual standard deviation of a
 2003 regression line or the standard deviation of y-intercepts of regression lines may be used as
 2004 the standard deviation.

2005 *III.2.7.4. Recommended data*

2006 The detection limit and the method used for determining the detection limit should be presented.

2007 In cases where an estimated value for the detection limit is obtained by calculation or extrapolation,
 2008 this estimate may subsequently be validated by the independent analysis of a suitable number of
 2009 samples known to be near or prepared at the detection limit.

2010 III.2.8. Quantitation limit

2011 Several approaches for determining the quantitation limit are possible, depending on whether the
 2012 procedure is non-instrumental or instrumental. Approaches other than those listed may be
 2013 acceptable.

2014 *III.2.8.1. Based on visual evaluation*

2015 Visual evaluation may be used for non-instrumental methods, but may also be used with
 2016 instrumental methods.

2017 The quantitation limit is generally determined by the analysis of samples with known
 2018 concentrations of analyte and by establishing the minimum level at which the analyte can be
 2019 quantified with acceptable accuracy and precision.

2020 *III.2.8.2. Based on signal-to-noise ratio*

2021 This approach can only be applied to analytical procedures which exhibit baseline noise.

2022 Determination of the signal-to-noise ratio is performed by comparing measured signals from
2023 samples with known low concentrations of analyte with those of blank samples and by establishing
2024 the minimum concentration at which the analyte can be reliably quantified. A typical signal-to-
2025 noise ratio is 10:1.

2026 *III.2.8.3. Based on the standard deviation of the response and the slope*

2027 The quantitation limit (QL) may be expressed as:

2028
$$QL = \frac{10\sigma}{S}$$

2029 σ = the standard deviation of the response,

2030 S = the slope of the calibration curve.

2031 The slope S may be estimated from the calibration curve of the analyte. The estimate of σ may
2032 be carried out in a variety of ways for example:

- 2033
- 2034 • Based on the standard deviation of the blank. Measurement of the magnitude of analytical
2035 background response is performed by analysing an appropriate number of blank samples
and calculating the standard deviation of these responses.
 - 2036 • Based on the calibration curve. A specific calibration curve should be studied using
2037 samples containing an analyte in the range of QL. The residual standard deviation of a
2038 regression line or the standard deviation of y-intercepts of regression lines may be used as
2039 the standard deviation.

2040 *III.2.8.4. Recommended data*

2041 The quantitation limit and the method used for determining the quantitation limit should be
2042 presented. The limit should be subsequently validated by the analysis of a suitable number of
2043 samples known to be near or prepared at the quantitation limit.

2044 **III.2.9. Robustness**

2045 The evaluation of robustness should be considered during the development phase and depends on
2046 the type of procedure under study. It should show the reliability of an analysis with respect to
2047 deliberate variations in method parameters.

2048 If measurements are susceptible to variations in analytical conditions, the analytical conditions
2049 should be suitably controlled or a precautionary statement should be included in the procedure.
2050 One consequence of the evaluation of robustness should be that a series of system suitability
2051 parameters (e.g. resolution test) is established to ensure that the validity of the analytical procedure
2052 is maintained whenever used.

2053 Typical variations are:

- 2054
- 2055 • stability of analytical solutions;
 - 2056 • different equipment;
 - 2057 • different analysts.

2058 In the case of LC, typical variations are:

- 2059 • influence of variations of pH in a mobile phase;
- 2060 • influence of variations in mobile phase composition;
- 2061 • different columns (different lots and/or suppliers);
- 2062 • temperature;
- 2063 • flow rate.

2064

2065 In the case of GC, typical variations are:

- 2066 • different columns (different lots and/or suppliers);
- 2067 • temperature;
- 2068 • flow rate.

2069

2070 III.2.10. System suitability testing

2071 System suitability testing is an integral part of many analytical procedures. The tests are based on
2072 the concept that the equipment, electronics, analytical operations and samples to be analysed
2073 constitute an integral system that can be evaluated as such. System suitability test parameters to
2074 be established for a particular procedure depend on the type of procedure being validated. See
2075 Pharmacopoeias for additional information.

2076

2077 III.3 SPECIFIC APPLICATION TO ANALYTICAL PROCEDURES USED IN THE
2078 PH. EUR.

2079 The following parts describe a number of points that are important for the validation of analytical
2080 procedures employing specific analytical techniques. These guidelines are to be used in conjunction
2081 with the general chapters of the Ph. Eur. and the validation requirements given previously in the
2082 ICH documents.

2083 III.3.1. Optical rotation (2.2.7)

2084 *III.3.1.1. Introduction*

2085 The solvent should be chosen in order to obtain an angle of rotation that is as great as possible. The
2086 stability of the angle of rotation of the solution should be checked over a period of at least
2087 2 hours. If necessary, the use of a freshly prepared solution may be prescribed. In exceptional cases,
2088 it may be necessary to prescribe an equilibration period before the measurement is carried out.
2089 Whenever possible, the use of a wavelength corresponding to the D-line of sodium (i.e. 589 nm) is
2090 prescribed.

2091 *III.3.1.2. Identification*

2092 When the substance examined is an enantiomer, the specific optical rotation is used for the
2093 identification.

2094 If the specific optical rotation is used for identification only, the result does not have to be

2095 calculated on the dried substance or the solvent-free substance. The limits prescribed should take
2096 into account any variation in content and purity of samples of different origin that comply with
2097 the monograph.

2098 *III.3.1.3. Tests*

2099 Specific optical rotation may be used to verify the optical purity of an enantiomer. This
2100 method is less sensitive than chiral LC. In the case where one enantiomer is to be limited by the
2101 measurement of specific optical rotation, then it is to be demonstrated that under the conditions of
2102 the test, the enantiomer has sufficient optical activity to be detected. The result is calculated on
2103 the dried substance or the solvent-free substance. Whenever possible, the influence of potential
2104 impurities should be reported. Limits for the specific optical rotation should be chosen with regard
2105 to the permitted amount of impurities. In the absence of information on the optical activity of related
2106 substances and when insufficient amounts of the related substances are available, the limits are
2107 usually arbitrarily fixed at $\pm 5\%$ around the mean value obtained for samples that comply with
2108 the monograph. Samples of different origin should be examined whenever possible. It is also
2109 worthwhile examining samples that are close to the expiry date to obtain information on the
2110 influence of normal ageing.

2111 Measurement of the angle of rotation may be used to verify the racemic character of a substance.
2112 In that case limits of -0.10° to $+0.10^\circ$ are usually prescribed.

2113 If possible, it is to be demonstrated that, under the conditions of the test, the enantiomer has
2114 sufficient optical activity to be detected.

2115

2116 **III.3.2. Absorption spectrophotometry (ultraviolet and visible) (2.2.25)**

2117 In all cases, the suitability of the operating conditions (solvents employed and their quality, pH of
2118 the solution, etc.), must be demonstrated.

2119 In normal use, ultraviolet spectrophotometry is a technique of limited discrimination power. The
2120 use of 1st- and 2nd-order derivative techniques may increase discrimination power.

2121 *III.3.2.1. Identification*

2122 Ultraviolet spectrophotometry is rarely the only procedure described for identification. When it is
2123 included in an identification series, discrimination power must be demonstrated by comparing the
2124 spectrum of the analyte with spectra of similar substances. Discrimination power can be increased
2125 by using absorbance ratios rather than absorbance values.

2126 *III.3.2.2. Limit test*

2127 When ultraviolet spectrophotometry is used for a limit test, it is to be demonstrated that at the
2128 appropriate wavelength, the related substance to be limited makes a sufficient contribution to the
2129 measured absorbance. The absorbance corresponding to the limiting concentration of the related
2130 substance must be established.

2131 *III.3.2.3. Assay*

2132 When ultraviolet spectrophotometry is used for the assay, the contribution to the absorbance of
2133 the known impurities must be evaluated. The use of specific absorbance values for assays is
2134 discouraged, but may be possible in dissolution tests in monographs on medicinal products (see the
2135 Technical guide for the elaboration of monographs on medicinal products containing chemically
2136 defined active substances). If specific absorbance values are prescribed, they must be evaluated by
2137 an inter-laboratory trial using a batch of known purity. Purity is to be estimated by applying a
2138 variety of techniques including separation techniques and absolute techniques.

2139 **III.3.3. Non-instrumental limit tests**2140 *III.3.3.1. Appearance of solution (2.2.1 and 2.2.2)*

2141 These simple visual tests compare the colour (or opalescence) of the test solution against a series of
2142 standards. Typically, the test solution should be clear and colourless. These tests are intended to
2143 give an assessment of the general purity of the substance. When degrees of colour (or
2144 opalescence) are permitted, the impurity and the level to which the degree of coloration (or
2145 opalescence) corresponds are often unknown. Validation is based on the examination of batch data
2146 supplied by the manufacturer(s). However, when the impurity causing the opalescence or colour is
2147 known, it may be possible to validate the visual test by comparison with a more sophisticated
2148 analytical technique.

2149 *III.3.3.2. Acidity or alkalinity*

2150 This is a general test of the purity of a substance. It is a non-specific test used for the control of
2151 protolytic impurities. The appropriate use of this test is described above.

2152 *III.3.3.3. Limit tests for anions/cations (2.4)*

2153 These are simple and rapid tests but they are to be shown to be appropriate by recovery experiments
2154 and/or comparison with other more sophisticated techniques.

2155 **Sulfated ash (2.4.14).** The sulfated ash test is intended as a global determination of cations
2156 present in organic substances but is obviously not applicable to inorganic salts of acidic organic
2157 substances. The limit is normally 0.1%. This gravimetric test controls the content of foreign cations
2158 to a level appropriate to indicate the quality of production. This method can be considered to be
2159 well established and no further validation is required.

2160 **Colour or precipitation reactions.** Limit tests are also described for individual cations and anions
2161 which are based on visual comparison of a colour or opalescence. It is essential that it is
2162 demonstrated that:

- 2163 • the colour or opalescence is visible at the target concentration (limit);
- 2164 • the recovery of added ion is the same for the test and reference solutions (by visual
2165 observation and if possible by absorbance measurement);
- 2166 • the response is sufficiently discriminating around the target value (50%, 100% and
2167 150% of the target value) by measuring the absorbances at an appropriate wavelength in
2168 the visible region;
- 2169 • a recovery experiment at the target value is carried out six times and the repeatability

2170 relative standard deviation (RSD) calculated. Recovery should be greater than 80% and
2171 the repeatability RSD should be not more than 20%.

2172
2173 It would be desirable, when appropriate, to compare the results obtained from a recovery experiment
2174 using the proposed limit test procedure with a quantitative determination using a different technique
2175 (e.g. atomic absorption spectrophotometry for cations or ion chromatography for anions). The
2176 results obtained by the two techniques are to be similar.

2177 III.3.4. Atomic absorption spectrometry (2.2.23)

2178 Atomic absorption spectrometry is exclusively employed in tests to determine the content of
2179 specific elements that are present in substances as impurities. The following validation requirements
2180 are particularly pertinent to atomic spectrometric methods. More validation requirements are given
2181 in the general chapter.

2182 *III.3.4.1. Specificity*

2183 In principle, this technique is specific, using the appropriate source and wavelength, for the element
2184 to be determined since the atom emits or absorbs radiation at discrete spectral lines. However,
2185 interferences may be encountered due to optical and/or chemical effects. Thus it is important to
2186 identify the interferences and, if possible, reduce their effect by using appropriate means before
2187 starting the validation programme.

2188 Such interferences may result in a systematic error if a direct calibration procedure is employed or
2189 may reduce the sensitivity of the technique. The most important sources of error in atomic
2190 spectrometry are associated with errors due to the calibration process and to matrix interference
2191 (care must be taken to avoid memory effects).

2192 *III.3.4.2. Calibration*

2193 Aqueous standards are prepared and analysed at different concentration levels, spread over the
2194 calibration range.

2195 The number of concentration levels at which standards must be prepared depends on the calibration
2196 model used. To demonstrate the applicability of a straight-line regression model, standards should
2197 be prepared at a minimum of four concentration levels. A parabolic regression model also requires
2198 at least four concentration levels. Preferably, the concentration levels are evenly distributed over
2199 the calibration range.

2200 Generally, it is recommended to perform at least five measurements at each concentration level.

2201 Calibration problems can often be detected visually. However, these plots alone cannot be used
2202 as proof of the suitability of the calibration procedure.

- 2203 • The measured absorbances are plotted as a function of the concentration, together with the
2204 curve that describes the calibration function and its confidence interval. This curve should
2205 fit the data points.
- 2206 • The residuals (i.e. the difference between the measured and the estimated absorbance)
2207 are plotted as a function of the concentration. When a suitable calibration procedure is
2208 applied, the residuals are randomly distributed around the x-axis.

2209

2210 When the variance of the signal increases with the concentration, as is often the case with
2211 atomic spectrometry and shown from either a plot of the residuals or with a one-tailed *t*-test, a
2212 weighted calibration model is better suited. Both linear and quadratic weighting functions are
2213 applied to the data to find the most appropriate weighting function to be employed.

2214 For a weighted model, the weighted residuals (i.e. the weight multiplied by the residual) are plotted
2215 as a function of the concentration:

- 2216 • the measured absorbances are plotted as a weighted function of the concentration,
2217 together with the curve that describes the calibration function and its confidence interval;
- 2218 • the weighted residuals are plotted as a function of the concentration.

2219

2220 It must be demonstrated that the data accurately fit the model. Application of a straight-line
2221 regression model implies that the linearity of the calibration line is investigated.

2222 *III.3.4.3. Matrix effects*

2223 When aqueous reference solutions are used to estimate the calibration function, it must be ensured
2224 that the sensitivities obtained with the sample solution and the aqueous solutions are similar.
2225 When a straight-line calibration model is applied, differences in sensitivity can be detected by
2226 comparing the slopes of standard addition and aqueous reference solutions calibration graphs. The
2227 quality of the estimation of the slopes of both regression lines depends on the number and
2228 distribution of the measurement points. Therefore, it is recommended to include sufficient
2229 measurement points (always > 5) in both regression lines, and to concentrate these points mainly
2230 on the extremes of the calibration range.

2231 The slopes of the standard addition line and the aqueous calibration line are compared, by applying
2232 a *t*-test, to check whether slopes of both regression lines are significantly different. If that is the
2233 case, then Method II (standard additions) is to be applied; if it is not the case, Method I (direct
2234 calibration) can be applied.

2235 *III.3.4.4. Detection and quantitation limit (based on the standard deviation of the blank)*

2236 To estimate the detection and quantitation limit, representative blanks are prepared and analysed.
2237 Preferably, matrix blanks are used, which contain every component of the sample except the
2238 analyte. However, when no matrix blanks are available, reagent blanks, containing all reagents and
2239 prepared in the same manner as the sample solution, can be used.

2240 Other aspects of the validation programme are covered above.

2241 III.3.5. Separation techniques

2242 The different chromatographic procedures (TLC, GC and LC) may be employed in the
2243 IDENTIFICATION section, in the TESTS section for the limitation of related substances and in the
2244 ASSAY section to determine the content of the active substance. The analytical procedures are to be
2245 validated according to the principles described previously, but there are specific aspects of the
2246 different chromatographic techniques that are to be taken into consideration. These are described
2247 below.

2248 *III.3.5.1. Thin-layer chromatography (2.2.27)*

2249 This chromatographic technique is widely employed in the Ph. Eur. for identification using a
2250 reference substance and for the limitation of impurities with or without the use of a reference
2251 substance. When impurities are to be determined quantitatively, appropriate instrumentation must
2252 be employed. For the most part, silica is employed as the stationary phase but reverse-phase
2253 stationary phases (e.g. silanised silica gel) or cellulose stationary phases are also employed.
2254 Nonetheless, the following points are common to the application of thin-layer chromatographic
2255 techniques whether used for identification or for a test for related substances.

- 2256 • Specificity: it is accepted that for an identification test, specificity cannot be attained
2257 using this technique alone but good discrimination can be expected. It must be
2258 accompanied by other tests which together assure specificity. Selectivity may not be
2259 attainable for a limit test, in which case one or more additional tests must be described to
2260 control the impurities not separated. Discrimination power is to be demonstrated. For an
2261 identification test, improvement in discrimination power can sometimes be achieved using
2262 a spray reagent that differentiates similar substances by colour.
- 2263 • Stationary phase: it is to be demonstrated that the test is applicable using plates of the
2264 same type but of different origin. Separations that can only be achieved on one particular
2265 type of plate are to be avoided, if possible.
- 2266 • Performance test (SST): such a test is generally performed to verify the separation of
2267 two closely eluting substances, the substance itself and a similar substance (critical pair).
2268 It is to be demonstrated that the separation of the chosen substances will guarantee the
2269 suitability of the chromatographic system. This performance criterion is essential for a test
2270 for related substances.

2271

2272 Additional aspects that require further documentation when TLC is applied to a test for related
2273 substances include:

- 2274 • Detection: the use of specific spray reagents must be avoided when applying a related
2275 substances test unless the test is designed to limit a named impurity using a reference
2276 substance.
- 2277 • Detection limit: when applying a quantitative instrumental procedure, one of the described
2278 methods for the calculation of the DL applies. When a visual method is applied, it is to be
2279 demonstrated that the quantity corresponding to the specified limit is detectable.
- 2280 • Response factors: if the known impurities are available, then the similarity of response
2281 factors (relative to the substance itself) is demonstrated using the given detection
2282 conditions. For a limit test, differences in response can be shown by comparison of the
2283 visual detection limits.
- 2284 • Quantitation limit, linearity, range and repeatability: data are also required when an
2285 instrumental quantitative TLC procedure is applied.

2286 *III.3.5.2. Liquid chromatography (2.2.29)*

2287 LC is usually applied to limit the content of impurities in a substance (employing an external
2288 standard, usually an appropriate dilution of the test solution), to determine the content of a substance
2289 (employing an external standard), and occasionally as an identification by cross-reference to one of
2290 the aforementioned procedures. Attention is to be paid to a number of aspects peculiar to LC.

2291 III.3.5.2.a. Identification

2292 It is accepted that for an identification test, specificity may not be attained using this technique but
 2293 good discrimination can be expected. It must be accompanied by other tests that together ensure
 2294 specificity. Discrimination power must be demonstrated with retention times, relative retentions or
 2295 mass distribution ratio of similar substances, and the substance itself, being reported. Such
 2296 information is to be supplied for a variety of stationary phases of a similar type.

2297 III.3.5.2.b. Limit test

- 2298 • Specificity:
 - 2299 ○ *Discrimination power of the separation*: separation of known and potential
 2300 impurities from the substance itself and if possible, from each other, must be
 2301 demonstrated. Specificity may be ensured by detection by mass spectrometry.
 2302 Impurities not separated from the substance must be controlled by another procedure.
 2303 The retention times, relative retention times or mass distribution ratio of the substance
 2304 and the impurities must be reported. Such information is to be supplied for a variety
 2305 of stationary phases of a similar type.
 - 2306 ○ *Discrimination power of the detection system*: the choice of the detector or the detector
 2307 conditions employed must be justified (e.g. change in the detection wavelength when
 2308 using UV detection) while specificity can be ensured by the use of detection by mass
 2309 spectrometry.
- 2310 • Response factors: it is essential to demonstrate the similarity of response of the substance
 2311 and known impurities (at the wavelength of detection for UV detection but applies also to
 2312 other detection systems, e.g. conductimetry). A response factor of a known impurity that
 2313 is greater than 1.2 or less than 0.8 compared to that of the substance to be examined may
 2314 require the use of either CFs or of that individual impurity as an external standard when
 2315 the proposed limit is 0.1% or greater.
- 2316 • Detection and quantitation limits: these limits must be determined for the external
 2317 standard, which is either a dilution of the substance to be examined or a known impurity.
 2318 When a peak of an impurity elutes close to the peak of the substance, particularly if it
 2319 elutes after the peak due to the substance, detection and quantitation limits are to be
 2320 determined on that impurity. One of the methods for calculation of both the DL and the
 2321 QL is applied.
- 2322 • Stability: data should be provided demonstrating the period of use of reference and test
 2323 solutions.
- 2324 • Recovery: when an extraction procedure is employed, a recovery experiment using
 2325 known and available impurities is to be carried out under optimal conditions and the results
 2326 reported. It is to be demonstrated that the recovery shows an acceptable accuracy and
 2327 precision.
- 2328 • Derivatisation: when pre- or post-column derivatisation is employed, it is important to
 2329 establish the optimal reaction conditions (time and temperature) and also to investigate
 2330 the stability of the derivative under normal conditions of use.
- 2331 • System suitability test: as described for TLC. The use of the S/N ratio is only required
 2332 when the DL and the specified limit are similar.

2333

2334 III.3.5.2.c. Assay

- 2335 • Specificity: this is preferable but not essential provided that the interfering impurity is

2336 present at a low level and is controlled by another test.

- 2337 • System suitability test: as described in general chapter 2.2.46. *Chromatographic*
2338 *separation techniques*. Table 2.2.46.-1 can be extended as follows:

	Number of individual injections				
	3	4	5	6	10
B (%)	Maximum permitted relative standard deviation				
1.0	0.21	0.30	0.37	0.42	0.60
1.5	0.31	0.44	0.55	0.64	0.90
2.0	0.41	0.59	0.73	0.85	1.20
2.5	0.52	0.74	0.92	1.06	1.51
3.0	0.62	0.89	1.10	1.27	1.81
3.5	0.72	1.04	1.22	1.48	2.11
4.0	0.83	1.19	1.46	1.70	2.41
4.5	0.93	1.33	1.65	1.91	2.71
5.0	1.04	1.48	1.83	2.12	3.01

2339

2340 Limit tests and assays must be validated as described above (see part III.2) for linearity,
2341 repeatability and reproducibility.

2342 *III.3.5.3. Gas chromatography (2.2.28)*

2343 *III.3.5.3.a. Identification*

2344 Specificity: as described for LC.

2345 *III.3.5.3.b. Limit test*

- 2346 • Specificity: as described for LC.
- 2347 • Response factors: as described for LC; response factors relative to the substance itself
2348 must be provided. This is particularly important when using selective detectors (ECD,
2349 NPD, etc.).
- 2350 • Detection and quantitation limits: as described for LC.
- 2351 • Stability: as described for LC.
- 2352 • Derivatisation: as described for LC.
- 2353 • Internal standard: it is to be demonstrated that under the chromatographic conditions
2354 employed, the peak due to the internal standard does not interfere with the impurity peaks
2355 or that due to the substance itself.
- 2356 • Recovery parameters: as described for LC.
- 2357

2358 *III.3.5.3.c. System suitability test*

2359 Details that are to be provided of chromatographic criteria to which a user must conform to
2360 successfully apply the test are as follows.

- 2361 • The S/N ratio is usually determined for a signal that is equal to or greater than the DL.
- 2362 • Resolution between the peak due to the substance and a closely eluting peak of an
2363 impurity or between the peak due to the substance and the peak due to the internal

2364 standard. It is also useful to give the acceptable range of values for the symmetry
 2365 factor when it is different from the accepted range of 0.8-1.8 as given in general chapter
 2366 2.2.46. This is particularly important when employing packed columns and when the peak
 2367 of an impurity to be controlled elutes immediately after the principal peak. Verification of
 2368 performance using a similar column, when possible, is recommended.

- 2369 • Head-space injection technique: this type of injection is employed for highly volatile
 2370 substances. It is important to demonstrate that the temperature and time of pre-heating of
 2371 the injection vial results in equilibrium conditions. The presence or absence of a matrix
 2372 effect should also be demonstrated. One way of validating head-space injection conditions
 2373 is to carry out multiple head-space extractions (after each injection, the head space is
 2374 vented and the vial is re-equilibrated before re-injection of the gaseous phase). The
 2375 pre-requisite for good conditions is that the relationship of the logarithms of the areas of
 2376 the analyte peak to the number of extractions is linear with a coefficient of regression of
 2377 1.0. Matrix effects can be overcome by the use of the standard addition technique.

2379 III.3.5.3.d. Assay

- 2380 • Specificity: as described for LC.
- 2381 • System suitability test: as described in general chapter 2.2.46. *Chromatographic*
 2382 *separation techniques* (see also part III.3.5.2.c).

2384 Limit tests and assays must be validated as described above (see part III.2) for linearity,
 2385 repeatability and reproducibility.

2386 III.3.5.3.e. Identification and control of residual solvents (2.4.24)

2387 The sample preparation and GC systems employed are to be validated for the substance to be
 2388 examined by applying the criteria given above with particular respect to:

- 2389 • specificity;
- 2390 • detection and quantitation limits;
- 2391 • recovery;
- 2392 • repeatability;
- 2393 • linearity, when employed quantitatively.

2394 III.3.6. Semi-micro determination of water (2.5.12)

2395 A number of commercial Karl Fischer reagents are available so it is important to ensure their
 2396 suitability for use by means of a validation procedure such as standard addition.

2397 *Standard addition*

2398 Determine the water content of the sample under the proposed conditions. Then, under airtight
 2399 conditions, add a suitable volume of a standardised solution of water in *methanol R* and
 2400 determine the water content m_{H_2O} as mg water. Repeat this step at least five times.

2401 Calculate the regression line of the cumulative water determined against the water added. Calculate
 2402 slope b , intercept with the ordinate a and intersection of the extrapolated calibration line with the
 2403 abscissa d .

2404 The slope b is to be between 0.975 and 1.025 (deviation $\pm 2.5\%$) to be acceptable. The
 2405 percentage errors e_1 and e_2 are lower than $\pm 2.5\%$.

$$e_1 = \frac{a - m_{H_2O}}{m_{H_2O}} \times 100 \qquad e_2 = \frac{|d| - m_{H_2O}}{m_{H_2O}} \times 100$$

Calculate the recovery of each standard addition step. The mean recovery is to be within 97.5% and 102.5% to be acceptable.

III.3.7. Volumetric titrations (2.5.11, 2.2.19, 2.2.20)

When developing a new volumetric assay procedure, it is recommended to titrate at least seven different quantities under the prescribed conditions in a randomised order to give end-point volumes in the range of 20-90% of the volume of the burette employed. Subsequently, the data are treated statistically and a number of criteria are to be fulfilled to permit acceptance of the titration procedure.

The relative error in reading of the mass on the balance and of the volume at the end-point is to be less than 0.5% of the values found.

The results, as end-point volumes V_i in dependence of mass m_i , are evaluated by linear regression. The regression line is calculated and characterised by the slope b_{obs} , the extrapolated intercept a_{obs} and the precision as $\sigma(V)$.

1st Criterion – Proportional Systematic Error (Bias)

The calculated slope b_{obs} , taking into account the titre of the standardised volumetric solution, is within 0.3% for potentiometric titrations (0.5% for visual titrations) compared to the theoretical value given as titration constant b_{theor} .

$$\left(\frac{b_{obs} - b_{theor}}{b_{theor}} \right) \times 100 \leq 0.3\% \text{ (0.5\% for visual determination)}$$

$$\text{where } b_{theor} = \frac{Z}{M_r C_r}$$

M_r is the relative molecular mass, Z is the stoichiometric factor of the chemical reaction and C_r is the molar concentration of the titrant.

2nd Criterion – Additional Systematic Error (Bias)

The extrapolated intercept a_{obs} is less than 0.4% for potentiometric titrations and 0.6% for visual titrations of the expected or target titration volume. This criterion may not be fulfilled if the titration is carried out too rapidly (potentiometric titration) or an unsuitable indicator has been employed (visual titration).

$$\left(\frac{a_{obs}}{V_T} \right) \times 100 < 0.4\% \text{ (0.6\% for visual determination)}$$

where a_{obs} is the extrapolated intercept of the regression line at zero and V_T is the expected or target titration volume.

3rd Criterion – Precision (Statistical Error)

The remaining estimated standard deviation $\sigma(V)$ is less than 0.3% for potentiometric titrations (0.5% for visual indicator titrations) of the mean titration volume of end-point using the titration procedure to be introduced in the monograph.

$$\left(\frac{\sigma(V)}{V_T}\right) \times 100 < 0.3\% \text{ (0.5\% for visual determination)}$$

where $\sigma(V)$ is the estimated standard deviation.

$$\sigma(V) = \sqrt{\frac{\sum(V_i - a_{obs} - b_{obs}m_i)^2}{n - 2}}$$

where V_i is the titration volume, m_i is the mass of the substance and n is the number of titrations performed.

4th Criterion – Practical Relative Error

Some titration procedures may not fulfil the first and second criteria but exhibit low and acceptable bias at the target titration volume ($8 \text{ mL} \pm 1 \text{ mL}$ for a 10 mL burette). Thus, if the first and/or the second criteria given above are not met, then calculate the relative accuracy at the target titration volume.

$$\left| \left(\frac{a_{obs}}{V_T} + \frac{b_{obs} - b_{theor}}{b_{theor}} \right) \right| \times 100$$

However, when the volumetric titration procedure is well established, it is sufficient to verify that the repeatability and accuracy of the titration (minimum 6 replicates) are not greater than the limits given in the table and decision tree below.


VOLUMETRIC TITRATION	CONTENT LIMITS (%)	REPEATABILITY (RSD)	RELATIVE ACCURACY (%)
Acid/base	± 1.0	0.33	± 0.67
Non-aqueous	± 1.0	0.33	± 0.67
Conjugate acid of base	± 1.0	0.33	± 0.67
Redox	± 1.5	0.5	± 1.0
Argentometric	± 1.5	0.5	± 1.0
Complexometric	± 2.0	0.67	± 1.33

The figures in the table are given as guidance and it may be demonstrated that stricter limits can be applied. The use of volumetric titrations is applicable only when it has been demonstrated that impurities are present at low levels, otherwise other assay methods are to be introduced.

Decision tree for validation of volumetric titrations

Repeatability: Relative standard deviation (RSD) over six replicate measurements ($n = 6$)

Relative accuracy: $\Delta\bar{V} = \frac{\bar{V} - V_{theory}}{V_{theory}}$



III.3.8. Peptide identification by nuclear magnetic resonance spectrometry (2.2.64)

The following factors should be addressed in procedure validation.

- Spectral consistency, to demonstrate that, within reasonable ranges, the spectrum obtained is independent of sample quantity, sample pH, analysis temperature (calibration error or recalibration changes) or mis-setting of spectral acquisition parameters such as pulse width. The effects of small changes in sample preparation procedures, such as deuterium exchange, should be considered. Analysis of a number of different batches of the test product should be included to demonstrate consistent spectra.
- Specificity: the spectrum of the test sample should be compared with those of other similar products handled on the same manufacturing site and shown to be distinctive, with notes of obvious spectral differences. The spectra of potential impurities could be assessed (especially specified impurities). These may be deamidated forms, variants containing a “wrong” amino acid enantiomer, or forms with an incorrect sequence. This approach should be similar to that used when assessing the specificity of chromatographic identity tests.
- Other variability:
 - operator-to-operator variability, expected to be small; it should be confirmed if more

- than one operator will undertake the test;
- spectrometer drift over time, probably negligible.

Minor revalidation will be required after probe servicing or console servicing, software upgrades or purchase of new spectrometer components; this can often be achieved using reference samples supplied with the spectrometer.

www.edqm.eu

The Council of Europe is the continent's leading human rights organisation. It comprises 46 member states, including all the members of the European Union. The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a directorate of the Council of Europe. Its mission is to contribute to the basic human right of access to good quality medicines and healthcare and to promote and protect public health.